Charles A. Dinarello

Charles A. Dinarello's AcademicInfluence.com Rankings

Biology

#360

World Rank

#641

Historical Rank

#209

USA Rank

Immunology

World Rank

Historical Rank

USA Rank

biology Degrees

Download Badge

Biology

Why Is Charles A. Dinarello Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Charles A. Dinarello is a professor of medicine at the University of Colorado at Denver. He is an expert on inflammatory cytokines, specifically Interleukin 1. Education and career Dinarello received his Doctor of Medicine in 1969 at Yale University and since 1996, he is Professor of Medicine at University of Colorado School of Medicine. He is also Professor of Experimental Medicine at the Radboud University Medical Center in Nijmegen, The Netherlands. Dinarello is considered one of the founding fathers of cytokines having purified and cloned interleukin-1. This important step established the validation of cytokines as mediators of disease, particularly of inflammation. Current studies blocking IL-1 in humans supports Dinarello's and his co-workers pivotal contributions to cytokine biology and the pathogenesis of inflammatory diseases.

(See a Problem?)

Charles A. Dinarello's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Biologic basis for interleukin-1 in disease. (1996) (4450)
Neuroinflammation in Alzheimer's disease (2015) (3620)
Immunological and inflammatory functions of the interleukin-1 family. (2009) (3126)
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). (1986) (2481)
Interleukin-1 and interleukin-1 antagonism. (1991) (2290)
Proinflammatory cytokines. (2000) (2006)
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. (2011) (1808)
Detection of circulating tumor necrosis factor after endotoxin administration. (1988) (1677)
Biology of interleukin 1 (1988) (1545)
The interleukin-1 family: back to the future. (2013) (1535)
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. (1986) (1478)
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 (1986) (1474)
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases (2012) (1465)
Interleukin-1 and its biologically related cytokines. (1989) (1188)
Interleukin-1 and the pathogenesis of the acute-phase response. (1984) (1101)
Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. (1990) (1034)
The role of interleukin-1 in disease. (1993) (996)
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. (1988) (979)
IL-1 is required for tumor invasiveness and angiogenesis (2003) (952)
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. (1984) (934)
Overview of the IL‐1 family in innate inflammation and acquired immunity (2018) (913)
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. (1987) (909)
The interleukin‐1 family: 10 years of discovery 1 (1994) (813)
IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. (1999) (813)
Anti-inflammatory Agents: Present and Future (2010) (813)
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. (1994) (812)
Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. (1998) (776)
Interleukin-1 immunoreactive innervation of the human hypothalamus. (1988) (775)
Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. (2009) (765)
Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. (1991) (745)
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. (1991) (706)
Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study (2003) (703)
A clinical perspective of IL‐1β as the gatekeeper of inflammation (2011) (692)
Historical insights into cytokines (2007) (665)
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. (1997) (662)
Interleukin-18 and IL-18 Binding Protein (2013) (650)
The IL-1 family and inflammatory diseases. (2002) (633)
Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. (1988) (615)
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. (1983) (612)
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. (1986) (604)
Inflammasome activation and IL-1β and IL-18 processing during infection. (2011) (604)
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* (2016) (591)
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. (1986) (580)
Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. (1994) (574)
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. (1998) (569)
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. (1986) (565)
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. (1987) (540)
Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. (1999) (523)
IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation (2009) (520)
Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. (1997) (518)
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. (1998) (518)
Blocking IL-1 in systemic inflammation (2005) (515)
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. (1986) (513)
Interleukin-32: a cytokine and inducer of TNFalpha. (2005) (511)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. (2014) (506)
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines (2002) (491)
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. (1984) (488)
Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. (2016) (483)
Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzyme a (1998) (468)
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. (2019) (452)
Interleukin 37 is a fundamental inhibitor of innate immunity (2010) (450)
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. (2001) (449)
Sleep-promoting effects of endogenous pyrogen (interleukin-1). (1984) (447)
Isolation of an interleukin-1-like factor from human joint effusions. (1983) (447)
Treating inflammation by blocking interleukin-1 in humans. (2013) (446)
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. (1986) (442)
A specific receptor antagonist for interleukin 1 prevents Escherichia coli‐induced shock in rabbits (1991) (438)
The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. (1991) (431)
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. (2000) (428)
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation (2011) (427)
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. (1999) (417)
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. (1995) (412)
Monocyte cytokine production in an elderly population: effect of age and inflammation. (1998) (411)
Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. (1989) (411)
Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. (1993) (406)
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. (1986) (403)
A guiding map for inflammation (2017) (402)
Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. (2003) (395)
Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. (1993) (388)
Cytokines as endogenous pyrogens. (1999) (384)
Interleukin-18 and Interleukin-1β: Two Cytokine Substrates for ICE (Caspase-1) (2004) (383)
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance (2006) (382)
Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation (2000) (381)
IL-1β-converting enzyme (caspase-1) in intestinal inflammation (2001) (379)
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1 (1985) (378)
Acute Toxoplasmosis Leads to Lethal Overproduction of Th1 Cytokines1 (2001) (377)
The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. (2000) (376)
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. (1999) (375)
Interleukin‐1α and Interleukin‐1 β in Preterm and Term Human Parturition (1992) (369)
New concepts on the pathogenesis of fever. (1988) (368)
Cisplatin-Induced Acute Renal Failure Is Associated with an Increase in the Cytokines Interleukin (IL)-1β, IL-18, IL-6, and Neutrophil Infiltration in the Kidney (2007) (362)
Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. (1987) (361)
Rapid responses to anakinra in patients with refractory adult-onset Still's disease. (2005) (360)
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. (1988) (358)
Multiple biological activities of human recombinant interleukin 1. (1986) (357)
Overview of interleukin‐18: more than an interferon‐γ inducing factor (1998) (356)
Increased plasma interleukin-1 activity in women after ovulation. (1985) (354)
Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. (2006) (354)
Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients (1994) (353)
Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. (1992) (350)
Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. (2000) (349)
The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. (2004) (347)
Interleukin-1 stimulates diacylglycerol production in T lymphocytes by a novel mechanism (1988) (346)
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. (1990) (345)
The biological properties of interleukin-1. (1994) (343)
Host and Environmental Factors Influencing Individual Human Cytokine Responses (2016) (341)
Immunoreactive interleukin-1β localization in the rat forebrain (1990) (337)
Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). (2010) (337)
IL-32, a proinflammatory cytokine in rheumatoid arthritis. (2006) (335)
IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. (2000) (333)
Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. (1986) (327)
IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction (2015) (326)
Colchicine therapy for familial mediterranean fever. A double-blind trial. (1974) (318)
Metabolic changes following eccentric exercise in trained and untrained men. (1986) (317)
The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo (2005) (317)
Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. (1989) (316)
Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation (2010) (316)
IL-37: a new anti-inflammatory cytokine of the IL-1 family. (2011) (316)
Interleukin-1 stimulates prostaglandin biosynthesis by human amnion. (1989) (315)
CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 (2005) (311)
Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β (2001) (310)
Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. (1992) (309)
Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. (1987) (307)
Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection (2013) (306)
Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. (2009) (304)
IL-1 family nomenclature (2010) (302)
Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor (1986) (302)
Interleukin 37 expression protects mice from colitis (2011) (301)
Interleukin-18 and host defense against infection. (2003) (297)
Inflammatory markers and the risk of Alzheimer disease (2007) (295)
IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist (2012) (291)
IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. (2005) (290)
Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. (2013) (288)
IL-1β mediates leptin induction during inflammation. (1998) (287)
Cytokine accumulations in CSF of multiple sclerosis patients (1990) (284)
Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. (1987) (282)
Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. (2007) (282)
Inflammasome-independent regulation of IL-1-family cytokines. (2015) (281)
Osmotic regulation of cytokine synthesis in vitro. (1995) (275)
Why not treat human cancer with interleukin-1 blockade? (2010) (269)
Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice1 (2006) (268)
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells (1993) (267)
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. (2008) (265)
Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-CSF. (1988) (265)
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. (2004) (264)
Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. (1991) (264)
Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1β* (2009) (264)
IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans (2014) (262)
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease (2020) (262)
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation (2018) (261)
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. (2001) (260)
IL-1 induction-capacity of defined lipopolysaccharide partial structures. (1989) (258)
Molecular basis of fever in humans. (1982) (258)
Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed (2004) (256)
Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. (1986) (255)
Interleukin-18 and the pathogenesis of inflammatory diseases. (2007) (254)
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). (1999) (253)
Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome (2017) (252)
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. (1991) (250)
Hemodialysis Hypotension: The Interleukin Hypothesis (1983) (250)
Interleukin-18, a proinflammatory cytokine. (2000) (250)
Dietary supplementation with n‐3 fatty acids suppresses interleukin‐2 production and mononuclear cell proliferation (1993) (248)
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. (1986) (248)
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes (2012) (247)
Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. (1997) (247)
Human leukocytic pyrogen: purification and development of a radioimmunoassay. (1977) (247)
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production (2001) (246)
Leptin deficiency enhances sensitivity to endotoxin-induced lethality. (1999) (245)
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. (2005) (245)
Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. (1991) (243)
Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. (1991) (242)
IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function (2010) (240)
IL‐1: Discoveries, controversies and future directions (2010) (240)
Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. (1998) (239)
Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. (2001) (239)
Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. (2011) (238)
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. (1989) (234)
Self-regulation of procoagulant events on the endothelial cell surface (1985) (233)
A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity (2002) (231)
Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation and Protects Mice Against Lethal Escherichia coli and Salmonella typhimurium Endotoxemia1 (2000) (229)
Differences in signaling pathways by IL-1beta and IL-18. (2004) (229)
Langerhans cell production of interleukin-1. (1984) (229)
Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. (1990) (228)
The IL-1 Family Member 7b Translocates to the Nucleus and Down-Regulates Proinflammatory Cytokines1 (2008) (227)
Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation (2018) (226)
IL-18 in autoimmunity: review. (2006) (226)
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. (1992) (224)
Reactive oxygen species–independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous disease (2010) (223)
Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. (1987) (221)
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. (2001) (221)
Mechanisms of fever induced by recombinant human interferon. (1984) (221)
Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. (1986) (220)
Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. (1990) (220)
Interleukin-18, more than a Th1 cytokine. (2013) (219)
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha (1988) (219)
Molecular Characterization of the Acute Inflammatory Response to Infections with Gram-Negative versus Gram-Positive Bacteria (2003) (217)
Interleukin-1beta and the autoinflammatory diseases. (2009) (216)
Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin 1. (1986) (213)
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. (1981) (212)
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). (2014) (211)
Role of IL-1β in type 2 diabetes (2010) (211)
Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. (1992) (211)
Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. (1987) (210)
Insulin‐Like Growth Factor‐1 and Interleukin 6 Predict Sarcopenia in Very Old Community‐Living Men and Women: The Framingham Heart Study (2003) (210)
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. (1984) (210)
Multiple cytokines stimulate hepatic lipid synthesis in vivo. (1989) (210)
Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. (1995) (209)
Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase (2013) (209)
Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. (1990) (209)
Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. (1993) (207)
Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. (1992) (206)
Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. (1991) (206)
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study (2011) (206)
Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. (2004) (206)
A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. (1996) (205)
Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. (2001) (203)
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. (2004) (203)
Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. (1997) (201)
The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis1 (2009) (201)
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. (2011) (200)
C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. (1987) (200)
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. (1978) (199)
DEMONSTRATION AND CHARACTERIZATION OF TWO DISTINCT HUMAN LEUKOCYTIC PYROGENS (1974) (199)
A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. (1988) (199)
Cytokines as mediators in the pathogenesis of septic shock. (1996) (197)
Suppression of inflammation and acquired immunity by IL‐37 (2018) (197)
Effect of endotoxin in IL-1 beta-deficient mice. (1996) (195)
The IL-1 family of cytokines and receptors in rheumatic diseases (2019) (195)
Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. (1994) (194)
IL-32, a novel cytokine with a possible role in disease (2006) (193)
Mycobacterium tuberculosis Induces Interleukin-32 Production through a Caspase- 1/IL-18/Interferon-γ-Dependent Mechanism (2006) (192)
IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. (2015) (191)
Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. (1982) (191)
Interleukin-1 alpha and interleukin-1 beta in preterm and term human parturition. (1992) (190)
Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis (1993) (190)
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. (2016) (190)
IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis (2016) (190)
Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice (2013) (189)
Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure (2012) (188)
Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8 (2015) (187)
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. (1991) (187)
Interleukin-18 Regulation of Interferon γ Production and Cell Proliferation as Shown in Interleukin-1β–Converting Enzyme (Caspase-1)-Deficient Mice (1998) (187)
IL-37 protects against obesity-induced inflammation and insulin resistance (2014) (184)
Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. (2004) (183)
Targeting innate immune mediators in type 1 and type 2 diabetes (2019) (180)
Occurrence of interleukin-1 in cerebrospinal fluid of the conscious cat (1988) (180)
Anakinra Therapy for Non-cancer Inflammatory Diseases (2018) (179)
Interleukin-1 augments gamma-aminobutyric acidA receptor function in brain. (1991) (179)
Suppression of innate inflammation and immunity by interleukin‐37 (2016) (179)
IL-12–induced IFN-γ is dependent on caspase-1 processing of the IL-18 precursor (1999) (179)
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. (1989) (178)
α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice (2008) (178)
Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses (2014) (177)
Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. (2005) (177)
NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome (2013) (177)
Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. (1988) (177)
The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines (2013) (176)
Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors (1991) (176)
In vitro production of IL 1β, IL 1α, TNF and IL 2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation (1989) (175)
Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. (2002) (174)
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. (1985) (173)
Biology of tumor necrosis factor‐α– implications for psoriasis (2004) (173)
Overview of the interleukin-1 family of ligands and receptors. (2013) (171)
Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen (1978) (171)
Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. (1997) (171)
The inflammatory response in interleukin‐1β‐deficient mice: comparison with other cytokine‐related knock‐out mice (1996) (171)
Interleukin-32A Cytokine and Inducer of TNFα (2005) (170)
α‐1‐Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood (2009) (170)
Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. (1987) (170)
Role of Interleukin‐l in Infectious Diseases (1992) (170)
Cytokines in Acute Myocardial Infarction: Selective Increase in Circulating Tumor Necrosis Factor, Its Soluble Receptor, and Interleukin‐1 Receptor Antagonist (1994) (169)
Identification of the most active interleukin‐32 isoform (2009) (168)
Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. (1992) (167)
Studies on the molecular nature of human interleukin 1. (1987) (167)
Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α (2011) (166)
Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. (2004) (165)
Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells (1991) (165)
Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro (1988) (165)
Elevated Intracranial IL-18 in Humans and Mice after Traumatic Brain Injury and Evidence of Neuroprotective Effects of IL-18—Binding Protein after Experimental Closed Head Injury (2002) (164)
Cytokines: agents provocateurs in hemodialysis? (1992) (164)
Interleukins in cancer: from biology to therapy (2021) (164)
IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. (2008) (163)
The paradox of pro-inflammatory cytokines in cancer (2006) (163)
Ventricular fluid interleukin-1 activity in patients with head injury. (1987) (163)
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 (2020) (163)
Differences in the synthesis and kinetics of release of interleukin 1α, interleukin 1β and tumor necrosis factor from human mononuclear cells (1989) (162)
Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. (1988) (162)
Pathogenesis of fever in man. (1978) (162)
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. (2015) (162)
Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer (2011) (161)
Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases (1991) (161)
Interleukin-32 induces the differentiation of monocytes into macrophage-like cells (2008) (160)
The Role of IL-1β in the Early Tumor Cell–Induced Angiogenic Response (2013) (160)
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines (1988) (158)
Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. (1988) (158)
Interleukin-1 and its receptor. (1989) (158)
Effects of progressive resistance training on immune response in aging and chronic inflammation. (1996) (156)
Interleukin-1β-induced Rat Pancreatic Islet Nitric Oxide Synthesis Requires Both the p38 and Extracellular Signal-regulated Kinase 1/2 Mitogen-activated Protein Kinases* (1998) (156)
Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. (2008) (155)
Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. (1997) (155)
Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. (1993) (153)
Proteinase 3 is an IL-32 binding protein. (2006) (152)
Adjuvant arthritis as a model of inflammatory cachexia. (1997) (151)
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. (2001) (151)
Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. (1994) (150)
Anti-cytokine therapeutics and infections. (2003) (150)
Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. (1994) (150)
Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. (2006) (149)
The biology of interleukin 1 and comparison to tumor necrosis factor. (1987) (148)
IL-1 beta mediates leptin induction during inflammation. (1998) (148)
Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness 1 (2003) (148)
Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells (2014) (147)
The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. (1983) (147)
Intrinsic Pituitary Interleukin-1β Is Induced by Bacterial Lipopolysaccharide* (1990) (146)
Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. (1994) (145)
Increased interleukin 1 beta in human skeletal muscle after exercise. (1989) (145)
IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. (1988) (145)
Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. (1988) (145)
Neonatal interleukin-1 beta, interleukin-6, and tumor necrosis factor: cord blood levels and cellular production. (1990) (143)
Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. (1991) (143)
Toll-like receptors and chronic inflammation in rheumatic diseases: new developments (2016) (143)
IL-37 Inhibits Inflammasome Activation and Disease Severity in Murine Aspergillosis (2014) (142)
TNF-α mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling (2005) (142)
Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans (2006) (141)
Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. (1984) (141)
Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. (1987) (140)
ENHANCEMENT OF IN-VITRO HUMAN INTERLEUKIN-1 PRODUCTION BY SODIUM ACETATE (1987) (139)
Mechanisms of Inhibition of Collagen-Induced Arthritis by Murine IL-18 Binding Protein 1 (2003) (139)
Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. (1998) (138)
The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. (1982) (138)
Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. (2016) (138)
The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). (1984) (138)
Resistant Behçet disease responsive to anakinra. (2008) (138)
Role of interleukin-1 in the depression of liver drug metabolism by endotoxin (1986) (137)
IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. (1990) (137)
The effects of interleukin 1 on human B cell activation and proliferation. (1983) (137)
Alarmins: Feel the Stress (2017) (136)
Hyperosmotic stress as a stimulant for proinflammatory cytokine production. (1997) (136)
Ability of Human Leukocytic Pyrogen to Stimulate Brain Prostaglandin Synthesis In Vitro (1982) (136)
Direct stimulation of the adrenal cortex by interleukin-1. (1987) (134)
Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-31 (2009) (134)
Blocking interleukin‐1β in acute and chronic autoinflammatory diseases (2011) (134)
Comparison of HDAC inhibitors in clinical development (2013) (134)
Non‐LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll‐like receptor 2‐dependent pathways (2002) (134)
Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function (2008) (133)
Both inflammatory and endocrine mediators stimulate host responses to sepsis. (1986) (133)
IL-6 and IL-8 production from cultured human endothelial cells stimulated by infection with Rickettsia conorii via a cell-associated IL-1 alpha-dependent pathway. (1995) (132)
The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. (2010) (131)
Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. (2011) (131)
Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). (2015) (131)
Induction of circulating IL-1 receptor antagonist by IFN treatment. (1993) (130)
The natural interleukin-1 receptor antagonist in term and preterm parturition. (1992) (130)
Innate Immune Response of Human Alveolar Macrophages during Influenza A Infection (2012) (129)
Human thymic epithelial cells produce interleukin 1. (1987) (128)
THE BIOLOGY OF SAA: IDENTIFICATION OF THE INDUCER, IN VITRO SYNTHESIS, AND HETEROGENEITY DEMONSTRATED WITH MONOCLONAL ANTIBODIES * (1982) (128)
IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease (2003) (128)
IL-32–dependent effects of IL-1β on endothelial cell functions (2009) (127)
The role of interferon-beta 1 and the 26-kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor. (1987) (126)
An IFN-γ-Independent Proinflammatory Role of IL-18 in Murine Streptococcal Cell Wall Arthritis (2000) (126)
Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. (1988) (126)
An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. (2005) (126)
Triggering receptor expressed on myeloid cells‐1 (TREM‐1) amplifies the signals induced by the NACHT‐LRR (NLR) pattern recognition receptors (2006) (125)
Recombinant tumor necrosis factor/cachectin and interleukin 1 pretreatment decreases lung oxidized glutathione accumulation, lung injury, and mortality in rats exposed to hyperoxia. (1987) (125)
Physiological mechanisms contributing to increased interleukin-1 secretion. (1986) (124)
Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. (1990) (124)
Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. (1998) (123)
Gender differences in IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. (1994) (123)
Cleavage of human interleukin 1: isolation of a peptide fragment from plasma of febrile humans and activated monocytes. (1984) (122)
Modulation of endothelial cell functions by different molecular species of interleukin 1. (1987) (122)
Human recombinant interleukin 1 beta has no effect on intracellular calcium or on functional responses of human neutrophils. (1987) (121)
Anakinra treatment in drug-resistant Behcet’s disease: a case series (2015) (120)
Imbalance between interleukin‐1 agonists and antagonists: relationship to severity of inflammatory bowel disease (2004) (120)
Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. (1995) (119)
Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. (1981) (119)
Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation (2011) (118)
Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. (1996) (118)
Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. (2015) (118)
Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells (2007) (117)
Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning. (1998) (116)
Endogenous IL-32 Controls Cytokine and HIV-1 Production1 (2008) (116)
Gene expression of interleukin-1β during hemodialysis (1993) (115)
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. (2014) (115)
Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. (1986) (115)
Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages (2001) (114)
Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression (2006) (113)
Measuring circulating cytokines. (1993) (112)
The many worlds of reducing interleukin-1. (2005) (112)
Interleukin‐1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse (2010) (111)
Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). (1986) (110)
Both E6 and E7 Oncoproteins of Human Papillomavirus 16 Inhibit IL-18-Induced IFN-γ Production in Human Peripheral Blood Mononuclear and NK Cells1 (2001) (110)
Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. (1996) (110)
Human monocyte or recombinant interleukin 1's are specific for the secretion of a metalloproteinase from chondrocytes. (1987) (110)
Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. (1986) (109)
Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. (1979) (109)
Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro. (1998) (109)
Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. (1986) (108)
A Polysaccharide Virulence Factor from Aspergillus fumigatus Elicits Anti-inflammatory Effects through Induction of Interleukin-1 Receptor Antagonist (2014) (108)
Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. (1996) (108)
Lipopolysaccharide induces human interleukin‐1 receptor antagonist and interleukin‐1 production in the same cell (1992) (108)
Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. (2007) (108)
Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells (2000) (108)
Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. (2014) (108)
Interleukin-1β in innate inflammation, autophagy and immunity. (2013) (107)
IL-32 Is a Host Protective Cytokine against Mycobacterium tuberculosis in Differentiated THP-1 Human Macrophages (2010) (107)
The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. (2001) (107)
Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir (2011) (106)
Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. (1992) (106)
Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. (1998) (105)
Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade (2010) (105)
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice (2008) (105)
Interleukin 18 stimulates HIV type 1 in monocytic cells. (1998) (104)
Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. (1990) (104)
Development and use of a radioimmunoassay for human interleukin-1 beta. (1987) (103)
The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. (1978) (103)
Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. (2003) (103)
Down modulation of IL‐18 expression by human papillomavirus type 16 E6 oncogene via binding to IL‐18 (2001) (102)
Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. (1988) (102)
Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1 (1988) (101)
Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells (1992) (101)
Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat) (2011) (101)
Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). (1990) (100)
Human interleukin-1 production during hemodialysis. (1986) (99)
Regulation of class III major histocompatibility complex gene products by interleukin-1. (1986) (99)
Interleukin-1 is released at sites of human cutaneous allergic reactions. (1990) (99)
INTERLEUKIN-1β STIMULATES SOMATOSTATIN BIOSYNTHESIS IN PRIMARY CULTURES OF FETAL RAT BRAIN (1989) (98)
Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. (1988) (98)
Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism (2018) (98)
Differential regulation of cytokine production in lipopolysaccharide tolerance in mice (1993) (97)
The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet β Cells In Vivo and In Vitro (2011) (97)
Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. (1993) (96)
A histamine-releasing factor from activated human mononuclear cells. (1985) (96)
Fever: Links with an ancient receptor (1999) (96)
Structure of a human serum amyloid A gene and modulation of its expression in transfected L cells. (1987) (96)
IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction (2009) (95)
The role of the liver in the production of fever and in pyrogenic tolerance. (1968) (95)
Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study (2016) (94)
Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. (1995) (94)
Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Comparison with IL-1 receptor antagonist. (1993) (94)
The biology of interleukin-1. (1992) (94)
The Rate of Interleukin-1β Secretion in Different Myeloid Cells Varies with the Extent of Redox Response to Toll-like Receptor Triggering* (2011) (94)
Interleukin-1 receptor antagonist suppresses contact hypersensitivity. (1995) (93)
Uric acid priming in human monocytes is driven by the AKT–PRAS40 autophagy pathway (2017) (93)
Pulmonary Inflammation Induced by Pseudomonas aeruginosa Lipopolysaccharide, Phospholipase C, and Exotoxin A: Role of Interferon Regulatory Factor 1 (2002) (93)
The IL‐36 receptor pathway regulates Aspergillus fumigatus‐induced Th1 and Th17 responses (2013) (93)
Interleukin-1 gene expression in rabbit vascular tissue in vivo. (1991) (93)
Physiological levels of interleukin‐18 stimulate multiple neutrophil functions through p38 MAP kinase activation (2002) (93)
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells (1990) (93)
p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. (1999) (93)
Interferon alpha-2 enhances slow-wave sleep in rabbits. (1987) (92)
The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. (1997) (92)
Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. (2005) (92)
Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin (1983) (92)
Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance (2015) (92)
A continuous delivery system of IL‐1 receptor antagonist reduces angiogenesis and inhibits tumor development (2004) (92)
An Expanding Role for Interleukin-1 Blockade from Gout to Cancer (2014) (91)
Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice (2017) (91)
Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. (1976) (90)
Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases (2015) (90)
Human Myocardial Tissue TNFαExpression Following Acute Global IschemiaIn Vivo (1998) (90)
Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α. (2011) (90)
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment (2018) (90)
Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. (2005) (89)
IL-18-Binding Protein Expression by Endothelial Cells and Macrophages Is Up-Regulated During Active Crohn’s Disease1 (2002) (88)
The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease (2020) (88)
Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. (2015) (88)
Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes. (1988) (88)
Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. (1991) (88)
Monokine Antagonism Is Reduced in Patients With IDDM (1994) (88)
IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. (2009) (87)
Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells (1998) (87)
IL-1 regulates in vivo C—X—C chemokine induction and neutrophil sequestration following endotoxemia (2002) (87)
Induction of tumor necrosis factor during extracorporeal blood purification. (1987) (87)
Cytokines increase rat lung antioxidant enzymes during exposure to hyperoxia. (1989) (87)
Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. (1989) (86)
Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. (1986) (86)
Transcriptional and inflammasome‐mediated pathways for the induction of IL‐1β production by Mycobacterium tuberculosis (2009) (86)
The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro (2010) (85)
Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. (2009) (85)
Plasma Levels of Interleukin-18 and Interleukin-18 Binding Protein Are Elevated in Patients with Chronic Liver Disease (2002) (85)
NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis (2018) (85)
Novel insights into the biology of interleukin-32 (2013) (85)
Studies on the ability of hemodialysis membranes to induce, bind, and clear human interleukin-1. (1988) (84)
Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. (1991) (84)
Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone. (2004) (84)
Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. (2005) (84)
Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. (1990) (84)
Plasma Cytokines, Cytokine Antagonists, and Disease Progression in African Women Infected with HIV-1 (1996) (84)
Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma (2012) (83)
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. (2020) (83)
IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. (1999) (83)
Adenosine reduces cardiac TNF-alpha production and human myocardial injury following ischemia-reperfusion. (1998) (83)
Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor beta increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. (1991) (83)
High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. (2010) (83)
Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes. (1987) (83)
Liposomal Delivery of Purified Inhibitory-κBα Inhibits Tumor Necrosis Factor-α–Induced Human Vascular Smooth Muscle Proliferation (1999) (82)
Leptin deficiency enhances sensitivity to endotoxin-induced lethality. (1999) (82)
TNF-α neutralization ameliorates obstruction-induced renal fibrosis and dysfunction (2007) (81)
Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. (2002) (81)
Interleukin‐1β (IL‐1β), IL‐1 receptor antagonist, and TNFα production in whole blood (1992) (81)
Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice. (1998) (81)
The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats (1993) (80)
Circulating interleukin‐1 and tumor necrosis factor antagonists in liver disease (1993) (80)
Interleukin‐1 (IL‐1) receptor blockade reduces endotoxin and Borrelia burgdorferi‐stimulated IL‐8 synthesis in human mononuclear cells (1992) (80)
TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. (2005) (80)
Multiple biological properties of recombinant human interleukin 1 (beta). (1986) (80)
Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. (1995) (79)
Functional Reconstitution and Regulation of IL-18 Activity by the IL-18Rβ Chain1 (2001) (79)
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and targeted treatment of autoimmune and inflammatory diseases. (2021) (78)
Bypassing pathogen-induced inflammasome activation for the regulation of interleukin-1beta production by the fungal pathogen Candida albicans. (2009) (77)
Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. (1993) (77)
Interleukin-1 and its relevance in patients treated with hemodialysis. (1988) (77)
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. (2017) (77)
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo (2016) (77)
IL-32 Promotes Angiogenesis (2014) (76)
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance (2017) (76)
Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children (2012) (76)
Regulation of early human hematopoietic (BFU-E and CFU-GEMM) progenitor cells in vitro by interleukin 1-induced fibroblast-conditioned medium. (1987) (76)
Beneficial effects of IL-37 after spinal cord injury in mice (2016) (75)
Paradoxical effects of constitutive human IL-32γ in transgenic mice during experimental colitis (2010) (75)
Interleukin‐32: A new proinflammatory cytokine involved in hepatitis C virus‐related liver inflammation and fibrosis (2011) (74)
Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. (1994) (74)
An update on human interleukin-1: From molecular biology to clinical relevance (1985) (73)
Interleukin‐1 and Glucocorticoid Hormones Integrate an Immunoregulatory Feedback Circuit a (1987) (73)
Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. (2008) (73)
Purified interleukin-1 (IL-1) from human monocytes stimulates acute-phase protein synthesis by rodent hepatocytes in vitro. (1987) (73)
Effect of interleukin-18 on mouse core body temperature. (2002) (73)
Biology of IL‐38 and its role in disease (2018) (73)
Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. (1995) (72)
Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. (2011) (72)
NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma (2017) (72)
IL-2 receptor(p55)/Tac-inducing factor. Purification and characterization of adult T cell leukemia-derived factor. (1988) (72)
Circulating lymphokine levels in the chronic fatigue syndrome. (1989) (72)
Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients (1988) (71)
Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases. (1992) (71)
IL‐18 Activity in Systemic Lupus Erythematosus (2009) (71)
Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens. (1989) (71)
Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits (1993) (71)
Thermoregulation and the pathogenesis of fever. (1996) (70)
Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. (1993) (70)
Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist. (1992) (70)
Interleukin-1 is a mucus secretagogue. (1991) (70)
Targeting interleukin 18 with interleukin 18 binding protein (2000) (70)
Pathogenic NLRP3 Inflammasome Activity during Candida Infection Is Negatively Regulated by IL-22 via Activation of NLRC4 and IL-1Ra. (2015) (70)
Interleukin 32 (IL-32) Contains a Typical α-Helix Bundle Structure That Resembles Focal Adhesion Targeting Region of Focal Adhesion Kinase-1* (2011) (70)
Detection of interleukin 1α and 1β in rabbit tissues during endotoxemia using sensitive radioimmunoassays (1991) (70)
Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. (1988) (70)
Control of protein degradation in muscle by prostaglandins, Ca2+, and leukocytic pyrogen (interleukin 1). (1984) (70)
The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis (2019) (70)
Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. (1998) (69)
Identification of the promoter region of human interleukin 1 type I receptor gene: multiple initiation sites, high G+C content, and constitutive expression. (1993) (69)
Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes : evidence for polygenecity in man (1994) (69)
Expression of interleukin‐1 receptor antagonist (IL‐1ra) by human circulating polymorphonuclear cells (1993) (69)
Modalities for reducing interleukin 1 activity in disease. (1993) (69)
Inhibitory effects of elevated temperature on human cytokine production and natural killer activity. (1986) (69)
Utilization of endoscopic inoculation in a mouse model of intrauterine infection-induced preterm birth: role of interleukin 1beta. (1999) (69)
Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. (2008) (69)
Blocking TH17‐polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo (2008) (69)
Differential Effects of Human lnterleukin‐1 on Growth of Human Fibroblasts and Vascular Smooth Muscle Cells (1985) (68)
Interplay between redox status and inflammasome activation. (2011) (68)
Recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hemopoietic growth factors in vitro. (1988) (68)
Regulation of eicosanoid production in rabbit colon by interleukin-1. (1989) (67)
Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans. (1986) (67)
Cytokine Measurements in Septic Shock (1993) (67)
Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. (1992) (67)
Neutrophil-Mediated Inhibition of Proinflammatory Cytokine Responses (2012) (67)
Ultrafiltration to reject human interleukin-1-inducing substances derived from bacterial cultures (1987) (67)
Interleukin-1β in human colostrum (1990) (67)
Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. (1980) (67)
Interleukin-18, together with interleukin-12, induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice (2008) (67)
P38 MAPK Mediates Myocardial Proinflammatory Cytokine Production and Endotoxin-Induced Contractile Suppression (2004) (66)
Interleukin-1 is a chemotactic factor for human T-lymphocytes. (1987) (66)
Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. (2007) (66)
Differential effects of interleukin-1 and tumor necrosis factor on ketogenesis. (1992) (66)
α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. (2018) (65)
Novel Strategies for Targeting Innate Immune Responses to Influenza (2016) (65)
Influence of dietary fatty acids on cytokine production and its clinical implications. (1993) (65)
Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. (1986) (64)
Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma (2016) (64)
Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. (2005) (64)
Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation (2013) (64)
Pathogenesis of sclerosing peritonitis in CAPD. (1984) (64)
Induction of interleukin-1 and interleukin-1 receptor antagonist. (1997) (64)
Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. (2008) (64)
Understanding human immune function using the resources from the Human Functional Genomics Project (2016) (63)
Prostaglandin E2 and thromboxane B2 in cerebrospinal fluid of afebrile and febrile cat. (1983) (63)
Intestinal Production of Interleukin-1α during Endotoxemia in the Mouse (1993) (63)
Treating Life-Threatening Myocarditis by Blocking Interleukin-1* (2016) (63)
Role of interleukin-1 in infectious diseases. (1992) (63)
IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity (2015) (63)
Identification of Amino Acid Residues Critical for Biological Activity in Human Interleukin-18* (2002) (62)
IL‐18 and infections: Is there a role for targeted therapies? (2020) (62)
The induction of interleukin-1 in humans and its metabolic effects. (1985) (62)
In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. (1992) (62)
Interleukin 1 reduces opioid binding in guinea pig brain (1985) (62)
The interleukin 1 receptor. (1989) (62)
Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines (2010) (62)
Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding Protein (2012) (61)
Stimulatory effect of interleukin-1 upon hepatic metabolism. (1986) (61)
The Role of Endogenous Interleukin (IL)-18, IL-12, IL-1β, and Tumor Necrosis Factor-α in the Production of Interferon-γ Induced by Candida albicans in Human Whole-Blood Cultures (2002) (60)
Increased interleukin 1β in human skeletal muscle after exercise (1989) (60)
Macrophage inflammatory protein-1 alpha production in lipopolysaccharide-stimulated human adherent blood mononuclear cells is inhibited by the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine. (1997) (60)
The role of interleukin 1 (IL 1) in tumor-NK cell interactions: correction of defective NK cell activity in cancer patients by treating target cells with IL 1. (1985) (60)
Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. (2012) (60)
Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein (2001) (60)
A Surface Amebic Cysteine Proteinase Inactivates Interleukin-18 (2003) (60)
Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra (2015) (60)
TREM-1 interaction with the LPS/TLR4 receptor complex. (2011) (59)
Proinflammatory Cytokines in Heart Disease (2001) (59)
Interleukin 1 Induces HIV-1 Expression in Chronically Infected U1 Cells: Blockade by Interleukin 1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein Type 1 (1995) (59)
Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. (2010) (59)
TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. (2007) (59)
Interleukin-1beta-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. (1998) (59)
Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. (1992) (59)
Selective regulation of intercellular adhesion molecule‐1 expression by interleukin‐18 and interleukin‐12 on human monocytes (2003) (59)
Extracellular superoxide dismutase haplotypes are associated with acute lung injury and mortality. (2009) (58)
Elevated plasma interleukin-1 levels in humans following ultraviolet light therapy for psoriasis. (1989) (58)
IL-1 Inhibition and Vascular Function in CKD. (2017) (58)
A method for removing interleukin-1- and tumor necrosis factor-inducing substances from bacterial cultures by ultrafiltration with polysulfone. (1989) (58)
Interleukin-1 induces natriuresis in conscious rats: role of renal prostaglandins. (1988) (57)
Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. (2010) (57)
Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. (2004) (57)
Recent advances in cytokines, cytokine receptors and signal transduction. (1998) (57)
Rabbit IL-1. Cloning, expression, biologic properties, and transcription during endotoxemia. (1989) (57)
The production of antibody against human leukocytic pyrogen. (1977) (56)
Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing? (1986) (56)
Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion (2021) (56)
Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine. (1986) (56)
Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. (2003) (56)
Clinical, hematologic, and immunologic effects of interleukin-10 in humans (1996) (56)
Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection (2014) (56)
Direct effects of a monoclonal B cell differentiation factor and of purified interleukin 1 on B cell differentiation. (1984) (56)
Thermal injury induces very early production of interleukin-1 alpha in the rat by mechanisms other than endotoxemia. (1994) (56)
Differential expression of interleukin‐32 in chronic rhinosinusitis with and without nasal polyps (2012) (55)
Immunoreactive interleukin-1 beta localization in the rat forebrain. (1990) (55)
Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: another paradox of longevity? (2003) (55)
Interleukin-1 as a mediator of fatigue in disease: a narrative review (2017) (55)
Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release. (2004) (55)
A radioimmunoassay for human interleukin-1a: measurement of IL-1a produced in vitro by human blood mononuclear cells stimulated with endotoxin (1988) (54)
Comparison of chemical analyses of hollow-fiber dialyzer extracts. (1984) (54)
Generation and characterization of mice transgenic for human IL‐18‐binding protein isoform a (2003) (54)
Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. (1992) (54)
Specific Inhibition of Histone Deacetylase 8 Reduces Gene Expression and Production of Proinflammatory Cytokines in Vitro and in Vivo* (2014) (54)
α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. (2014) (54)
Influence of Prostaglandins (1989) (54)
Role of Interleukin-18 in Host Defense against Disseminated Candida albicans Infection (2002) (53)
Introduction to the interleukin‐1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity (2018) (53)
Role of interferon regulatory factor‐1 in the regulation of IL‐18 production and activity (2001) (53)
Interleukin-1 favours the in vitro development of type 2 T helper (Th2) human T-cell clones. (1994) (53)
Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. (1992) (53)
Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. (2017) (53)
Interleukin-1 enhances pain reflexes. Mediation through increased prostaglandin E2 levels (1988) (53)
How interleukin-1β induces gouty arthritis. (2010) (52)
Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor (2006) (52)
Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. (1995) (52)
Release of lymphokines after infection with Epstein Barr virus in vitro. II. A monocyte-dependent inhibitor of interleukin 1 downregulates the production of interleukin 2 and interferon-gamma in rheumatoid arthritis. (1986) (52)
Anti-cytokine therapies in response to systemic infection. (2001) (52)
Tumor necrosis factor-alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. (1991) (52)
Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating experimental autoimmune encephalomyelitis in Lewis rats. (1987) (52)
Ciliary neurotrophic factor is an endogenous pyrogen. (1993) (51)
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. (1997) (51)
α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. (2014) (51)
Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. (2017) (50)
Production of endogenous pyrogen. (1979) (50)
Interferon‐α induces interleukin‐18 binding protein in chronic hepatitis C patients (2002) (50)
Novel targets for interleukin 18 binding protein (2001) (50)
ELISA kits based on monoclonal antibodies do not measure total IL-1β synthesis (1992) (50)
Recombinant human interleukin-1 beta causes histamine release from human basophils. (1988) (50)
Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure (2017) (50)
A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. (1989) (50)
Human leukocytic pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli (1984) (49)
Characterization of polymorphisms of an interleukin 1 receptor type 1 gene (IL1RI) promotor region (P2) and their relation to insulin-dependent diabetes mellitus (IDDM). The Danish Study Group of Diabetes in Childhood. (1995) (49)
Purified, 35S-Met, 3H-Leu-Labelled Human Monocyte Interleukin-1 (IL-1) with Endogenous Pyrogen Activity (1985) (49)
Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor, interleukin 1, and interleukin 6 but not by interferon-alpha. (1991) (49)
Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. (2007) (49)
Immunoregulatory functions of paf-acether. IV. Enhancement of IL-1 production by muramyl dipeptide-stimulated monocytes. (1990) (49)
Antigen presentation by EBV-B cells to resting and activated T cells: role of interleukin 1. (1985) (48)
Antiviral and immunoregulatory activities of IFN-γ depend on constitutively expressed IL-1α (2007) (48)
Anti-cytokine strategies. (1992) (48)
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. (2017) (48)
Induction by IL 1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 1986. 137: 245-254. (2011) (47)
Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses (2015) (47)
Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production (1993) (47)
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease (2019) (47)
Effects of human interleukin 1 and human tumor necrosis factor on human T lymphocyte colony formation. (1987) (47)
Monokines and Other Non-Lymphocytic Cytokines (1989) (47)
Ozone exposure of macrophages induces an alveolar epithelial chemokine response through IL-1alpha. (2008) (47)
Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. (2004) (47)
Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans (1987) (46)
Plasmapheresis for fulminant meningococcemia. (1989) (46)
Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell‐associated IL‐1α (2006) (46)
Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. (2016) (46)
Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. (1996) (46)
Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. (2016) (46)
OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis (2019) (45)
The Pathogenic Th17 Cell Response to Major Schistosome Egg Antigen Is Sequentially Dependent on IL-23 and IL-1β (2011) (45)
The history of fever, leukocytic pyrogen and interleukin-1 (2015) (45)
Tetramethoxy Hydroxyflavone p7F Downregulates Inflammatory Mediators via the Inhibition of Nuclear Factor κB (2004) (45)
Cellular interactions in the generation and expression of histamine-induced suppressor activity. (1982) (45)
Expression of biologically active human interleukin 1 subpeptides by transfected simian COS cells. (1986) (45)
Proximal tubules from caspase-1-deficient mice are protected against hypoxia-induced membrane injury. (2007) (45)
Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin. (2016) (44)
Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. (1996) (44)
Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism. (1992) (44)
Setting the cytokine trap for autoimmunity (2003) (44)
Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis (2015) (44)
A signal for the caspase-1 inflammasome free of TLR. (2007) (44)
Human and murine interleukin 1 possess sequence and structural similarities. (1985) (43)
Treating pulmonary silicosis by blocking interleukin 1. (2015) (43)
Physiological and cytokine responses in IL-1 beta-deficient mice after zymosan-induced inflammation. (1997) (42)
Comparison of the effect of interleukin 6 and interleukin 1 on collagenase and proteoglycan production by chondrocytes. (1990) (42)
Production of leukocytic pyrogen from phagocytes of neonates. (1981) (42)
Cytokines and biocompatibility. (1990) (42)
In vitro enhanced thromboxane B2 release by polymorphonuclear leukocytes and macrophages after treatment with human recombinant interleukin 1. (1986) (42)
In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. (1989) (42)
Interleukin‐1 in the pathogenesis of fever (1987) (42)
Human myocardial tissue TNFalpha expression following acute global ischemia in vivo. (1998) (42)
Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo (2016) (41)
Peripheral Blood Neutrophil Activation Patterns Are Associated with Pulmonary Inflammatory Responses to Lipopolysaccharide in Humans1 (2006) (41)
Brain temperature changes coupled to sleep states persist during interleukin 1-enhanced sleep. (1986) (41)
Interleukin-18 inhibits human immunodeficiency virus type 1 production in peripheral blood mononuclear cells. (2001) (41)
Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness. (2004) (41)
Production of cytokines and cytokine inhibitory proteins in patients on dialysis. (1994) (41)
Ciliary neurotrophic factor (CNTF) induces serum amyloid A, hypoglycaemia and anorexia, and potentiates IL-1 induced corticosterone and IL-6 production in mice. (1995) (41)
Ultrafiltration to remove endotoxins and other cytokine-inducing materials from tissue culture media and parenteral fluids. (1990) (41)
Increased Cytokine Production in Interleukin-18 Receptor α-deficient Cells Is Associated with Dysregulation of Suppressors of Cytokine Signaling* (2009) (41)
Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study). (2015) (41)
Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. (1994) (41)
Towards a role of interleukin-32 in atherosclerosis. (2013) (40)
Interleukin‐1 affects the function of cultured human thyroid cells (1988) (40)
Interleukin-18 mRNA, but not interleukin-18 receptor mRNA, is constitutively expressed in islet beta-cells and up-regulated by interferon-gamma. (2000) (40)
Interleukin-18 and the treatment of rheumatoid arthritis. (2004) (40)
Coagulation of Whole Blood Stimulates Interleukin-1β Gene Expression (1995) (40)
Abnormal epigenetic changes during differentiation of human skeletal muscle stem cells from obese subjects (2017) (40)
Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. (2000) (40)
IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease. (2011) (40)
Role of IL-18 in second-hand smoke-induced emphysema. (2013) (39)
An anti-inflammatory property of Candida albicans β-glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism. (2015) (39)
The interaction between myocardial depressant factors in endotoxemic cardiac dysfunction: role of TNF-alpha in TLR4-mediated ICAM-1 expression. (2007) (39)
Interleukin‐1, Anorexia, and Dietary Fatty Acids a (1990) (39)
Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury. (2008) (39)
Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells. (1997) (38)
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. (1994) (38)
ATP-Induced IL-1β Specific Secretion: True Under Stringent Conditions (2015) (38)
Role of interleukin 1 in antigen-specific T cell proliferation. (1984) (37)
Peptides modulating conformational changes in secreted chaperones: From in silico design to preclinical proof of concept (2009) (37)
Neutralization of IL-1α ameliorates Crohn’s disease-like ileitis by functional alterations of the gut microbiome (2019) (37)
Mechanisms of loss of lean body mass in patients on chronic dialysis. (1996) (37)
Protection from RNA and DNA Viruses by IL-32 (2011) (37)
Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain. (2001) (37)
The endogenous pyrogens in host-defense interactions. (1989) (37)
Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue (2018) (37)
Synthetic peptide corresponding to a conserved domain of the retroviral protein p15E blocks IL-1-mediated signal transduction. (1989) (37)
Role for nuclear interleukin-37 in the suppression of innate immunity (2019) (37)
Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species (2017) (37)
The Biology of Interleukin-1 (Part 1 of 2) (1992) (37)
Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. (2007) (37)
Frontline: Interferon regulatory factor‐1 as a protective gene in intestinal inflammation: role of TCR γ δ T cells and interleukin‐18‐binding protein (2004) (36)
Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy. (1992) (36)
Identification of a Critical Ig-Like Domain in IL-18 Receptor α and Characterization of a Functional IL-18 Receptor Complex 1 (2003) (36)
Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production. (1993) (36)
Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein. (1998) (36)
Interaction of IL 1 and TPA in modulation of eosinophil function. (1986) (36)
Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response (2005) (36)
Cytokine - Processing Enzymes: Stopping the cuts (1995) (36)
Interleukins. (1985) (36)
β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo. (2012) (36)
Deficient autophagy unravels the ROS paradox in chronic granulomatous disease (2014) (36)
IL-32γ and Streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2 (2010) (36)
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV‐1 replication (1995) (36)
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout (2020) (36)
Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. (2006) (36)
α1-Antitrypsin Combines with Plasma Fatty Acids and Induces Angiopoietin-like Protein 4 Expression (2015) (36)
Human monocyte-derived soluble product(s) has an accessory function in the generation of histamine- and concanavalin A-induced suppressor T cells. (1982) (35)
Interleukin-1 receptor type I mRNA in mouse brain as affected by peripheral administration of bacterial lipopolysaccharide (1994) (35)
IL-37 Suppresses MyD88-mediated Inflammatory Responses in Human Aortic Valve Interstitial Cells (2017) (35)
Interleukin-6 and tumor necrosis factor in cerebrospinal fluid: changes during pyrogen fever (1993) (35)
Altered interleukin-1 and tumor necrosis factor production and secretion during pyrogenic tolerance to LPS in rabbits. (1994) (35)
Nocardiosis in a child with chronic granulomatous disease. (1973) (35)
Modalities for reducing interleukin 1 activity in disease. (1993) (35)
Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. (1998) (35)
Alpha-1-antitrypsin Therapy Ameliorates Acute Colitis and Chronic Murine Ileitis (2013) (35)
The Inter-Relationship of Platelets with Interleukin-1β-Mediated Inflammation in Humans (2018) (35)
Effects of cytokines on human thymic epithelial cells in culture. II. Recombinant IL 1 stimulates thymic epithelial cells to produce IL6 and GM-CSF. (1990) (35)
Cytokines, Acute Phase Proteins, and Tissue Injury (1990) (35)
Interleukin-37 monomer is the active form for reducing innate immunity (2019) (34)
The effect of whole body hyperthermia on the immune cell activity of cancer patients. (1990) (34)
A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma. (2013) (34)
Interleukins, Tumor Necrosis Factors (Cachectin), and Interferons as Endogenous Pyrogens and Mediators of Fever (1987) (34)
Purification and characterization of a unique human interleukin 1 from the tumor cell line U937. (1986) (33)
Fish lymphocytes respond to human IL-1. (1986) (33)
Differential Roles of Interleukin-18 (IL-18) and IL-12 for Induction of Gamma Interferon by Staphylococcal Cell Wall Components and Superantigens (2001) (33)
Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease (2019) (33)
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. (2002) (33)
Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice. (1997) (33)
Does blocking cytokines in sepsis work? (2002) (32)
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. (1993) (32)
Intravitreal Anakinra Inhibits Choroidal Neovascular Membrane Growth in a Rat Model (2009) (32)
Human vascular smooth muscle cells produce an intracellular form of interleukin-1 receptor antagonist. (1995) (32)
Interleukin-1α neutralisation in patients with cancer. (2014) (32)
Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury. (1999) (32)
Fibroblast stimulation in schistosomiasis. V. Egg granuloma macrophages spontaneously secrete a fibroblast-stimulating factor. (1984) (32)
Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir (2015) (32)
Gene expression of interleukin-1 beta during hemodialysis. (1993) (32)
Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. (1999) (31)
Interleukin 18 and Interleukin 18 Binding Protein: Possible Role in Immunosuppression of Chronic Renal Failure (2003) (31)
Interleukin-18 Binding Protein in the Sera of Patients with Wegener’s Granulomatosis (2008) (31)
The role of interleukin-1 in host responses to infectious diseases. (1992) (31)
Individual LPS responsiveness depends on the variation of toll-like receptor (TLR) expression level. (2007) (31)
Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo. (1996) (31)
Parasite-monocyte interactions in human leishmaniasis: production of interleukin-1 in vitro. (1985) (31)
in Human Vascular Smooth Muscle Cells (1986) (31)
Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes--evidence for polygenicity in man. Danish Study Group of Diabetes in Childhood. (1994) (31)
Regulation of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. (2003) (30)
IL‐12 and IL‐18 induce MAP kinase‐dependent adhesion of T cells to extracellular matrix components (2002) (30)
Short‐term interleukin‐37 treatment improves vascular endothelial function, endurance exercise capacity, and whole‐body glucose metabolism in old mice (2019) (30)
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. (2021) (30)
Host-Derived Interleukin-1α Is Important in Determining the Immunogenicity of 3-Methylcholantrene Tumor Cells1 (2009) (30)
The Combination of Soluble IL-18Rα and IL-18Rβ Chains Inhibits IL-18-Induced IFN-γ (2002) (30)
Demonstration of a human pyrogen-inducing factor during mixed leukocyte reactions (1981) (29)
Interleukin-1 and the response to injury (1989) (29)
Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide (1987) (29)
A primate model for the study of human fever. (1975) (29)
Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF‐α, IFN‐γ and glucocorticoids (2005) (29)
Does the Route of Feeding Modify the Inflammatory Response? (1994) (29)
Biologic activities of interleukin-1 relevant to rheumatic diseases. (1987) (29)
Role of glutathione metabolism in host defense against Borrelia burgdorferi infection (2018) (29)
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. (2018) (29)
Effect of Recombinant α1-Antitrypsin Fc-Fused (AAT-Fc) Protein on the Inhibition of Inflammatory Cytokine Production and Streptozotocin-Induced Diabetes (2013) (29)
Studies on IL-1 receptors on D10S T-helper cells: demonstration of two molecularly and antigenically distinct IL-1 binding proteins. (1989) (28)
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy. (1993) (28)
Pharmacology of Cytokines (2000) (28)
Interleukin-1--its multiple biological effects and its association with hemodialysis. (1988) (28)
The Biology of Interleukin-1 and Its Relevance to Hemodialysis (1983) (28)
Prostaglandin formation in feline cerebral microvessels: effect of endotoxin and interleukin-1. (1987) (28)
Interleukin-1 and interleukin-1 receptor antagonist. (1995) (28)
Proteinase 3-processed form of the recombinant IL-32 separate domain. (2008) (28)
Characterization of Limulus amoebocyte lysate-reactive material from hollow-fiber dialyzers (1984) (28)
Caspase-3-independent apoptotic pathways contribute to interleukin-32γ-mediated control of Mycobacterium tuberculosis infection in THP-1 cells (2015) (27)
Differential susceptibility to lethal endotoxaemia in mice deficient in IL‐1α, IL‐1β or IL‐1 receptor type I (2010) (27)
Modulation of human chondrocyte metabolism by recombinant human interferon gamma: in-vitro effects on basal and IL-1-stimulated proteinase production, cartilage degradation and DNA synthesis. (1989) (27)
Interleukin-1 antagonists. (1994) (27)
Effects of Purified Human Interleukin-1 on the Release of Prostaglandin E2 from Fibroblasts (1985) (27)
Demonstration of circulating leukocytic pyrogen/interleukin-1 during fever. (1984) (27)
CHAPTER 27 – Interleukin-1 Family [IL-1F1, F2] (2003) (27)
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes (2013) (26)
Immunodeficiency with defective T-cell response to interleukin 1. (1984) (26)
Alveolar type II cells inhibit fibroblast proliferation: role of IL-1alpha. (2006) (26)
Pathogenesis of fever during hemodialysis. (1983) (26)
Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? (1995) (26)
Recombinant interleukin 1 and tumor necrosis factor acting in synergy to release thromboxane, 6-KETO-PGF1 alpha and PGE2 by human neutrophils. (1988) (26)
Intrinsic pituitary interleukin-1 beta is induced by bacterial lipopolysaccharide. (1990) (26)
Ciliary Neurotrophic Factor Combined with Soluble Receptor Inhibits Synthesis of Proinflammatory Cytokines and Prostaglandin-E2in Vitro (1994) (26)
A Switch to High-Flux Helixone® Membranes Reverses Suppressed Interferon-γ Production in Patients on Low-Flux Dialysis (2003) (26)
Transcription, translation and secretion of interleukin 1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5‐lipoxygenase inhibitor (1991) (26)
α-Linoleic Acid Enhances the Capacity of α1-Antitrypsin to Inhibit Lipopolysaccharide-Induced IL-1β in Human Blood Neutrophils (2016) (26)
Blocking interleukin-1 receptors (1994) (26)
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer (2018) (26)
Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease (1989) (26)
Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells. (1987) (25)
Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells (2021) (25)
Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance (2016) (25)
Cytokine gene expression and synthesis by human megakaryocytic cells. (1992) (25)
The role of endogenous interleukin (IL)-18, IL-12, IL-1beta, and tumor necrosis factor-alpha in the production of interferon-gamma induced by Candida albicans in human whole-blood cultures. (2002) (25)
Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37 (2015) (25)
Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. (1996) (25)
Linkage disequilibrium testing of four interleukin-1 gene-cluster polymorphisms in Danish multiplex families with insulin-dependent diabetes mellitus. (2000) (25)
Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. (1988) (25)
Abstract of the second international conference on immunopharmacologyHuman natural killer activity: Effects of leukocytic pyrogen/lymphocyte activating factor (LP/LAF), T-cell growth factor (TCGF), and interferon (IFN) (1982) (25)
CAPD is a second-class treatment. (1985) (25)
Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). (1995) (25)
Interleukin‐37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice (2017) (25)
β2-MICROGLOBULIN AND HAEMODIALYSIS (1987) (25)
Interleukin 1 production by human lung tissue. I. Identification and characterization. (1987) (24)
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. USA 1984. 81: 7907-7911. (2007) (24)
Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis (2019) (24)
Blocking interleukin-1 in disease. (1993) (24)
The effect of interleukin 1 on IgG synthesis in systemic lupus erythematosus. (1987) (24)
Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. (2009) (24)
Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-alpha2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. (1998) (24)
Induction of acute phase reactants by interleukin-1 (1984) (24)
Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? (2015) (24)
Inhibitors of histone deacetylases as anti-inflammatory drugs. (2006) (24)
Glycosylation of the interleukin-1 receptor type I is required for optimal binding of interleukin-1. (1992) (24)
Effect of protein depletion and short-term parenteral refeeding on the host response to interleukin 1 administration. (1987) (24)
Three distinct promoters direct transcription of different 5' untranslated regions of the human interleukin 1 type I receptor: a possible mechanism for control of translation. (1996) (24)
Central effects of vasopressin and 1-desamino-8-d-arginine vasopressin (DDAVP) on interleukin-1 fever in the rat (1987) (23)
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. (1995) (23)
Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression (2019) (23)
Pro-interleukin-1 beta production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2. (1990) (23)
Removal of Circulating Cytokines by Hemodialysis Membranes In Vitro (1993) (23)
TNF receptor I is required for induction of macrophage heat shock protein 70. (2001) (23)
Normal Free Interleukin-18 (IL-18) Plasma Levels in Dengue Virus Infection and the Need To Measure Both Total IL-18 and IL-18 Binding Protein Levels (2015) (23)
Acute-Phase Protein α1-Antitrypsin—A Novel Regulator of Angiopoietin-like Protein 4 Transcription and Secretion (2014) (23)
Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression (2021) (23)
New Polyether Sulfone Dialyzers Attenuate Passage of Cytokine- Inducing Substances from Pseudomonas aeruginosa Contaminated Dialysate (1998) (22)
Interleukin-1 beta in human colostrum. (1990) (22)
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. (1994) (22)
IL-37 Causes Excessive Inflammation and Tissue Damage in Murine Pneumococcal Pneumonia (2017) (22)
The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients (2015) (22)
Cytokines as potential therapeutic targets for inflammatory skin diseases. (2005) (22)
Interleukin-1 in disease. (1994) (22)
Anakinra for the inflammatory complications of chronic granulomatous disease. (2011) (22)
Interleukin 4 (IL) 4 up‐regulates gene and surface IL 1 receptor type I in murine T helper type 2 cells (1992) (22)
IL-32γ promotes the healing of murine cutaneous lesions caused by Leishmania braziliensis infection in contrast to Leishmania amazonensis (2017) (21)
Interleukin-1α as an intracellular alarmin in cancer biology. (2018) (21)
Human Alpha-1-Antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury (2017) (21)
Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. (2002) (21)
IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis (2017) (21)
Interleukin-1 receptor antagonist transiently impairs antibacterial defense but not survival in murine pneumococcal pneumonia. (2003) (21)
Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist (1994) (21)
Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects (2019) (21)
Interleukin-1 receptor antagonist: an index of dialysis-induced interleukin-1 production. (1994) (21)
Cytokine Inhibition in Patients With Chronic Fatigue Syndrome (2017) (21)
Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. (1998) (21)
Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. (2001) (21)
Overview of inflammatory cytokines and their role in pain (1999) (20)
ELISA kits based on monoclonal antibodies do not measure total IL-1 beta synthesis. (1992) (20)
Interleukin 1 as mediator of the acute-phase response (1984) (20)
Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats (1993) (20)
[Cytokines in the pathogenesis of fever]. (1989) (20)
Anti‐interleukin‐1 reactive cells in Hodgkin's disease (1987) (20)
The specific IL-1 inhibitor from the human M20 cell line is distinct from the IL-1 receptor antagonist. (1991) (20)
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. (1996) (20)
Role of interleukin-1 and tumour necrosis factor-a in acute inflammation (1987) (20)
Frontline: interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR gamma delta T cells and interleukin-18-binding protein. (2004) (20)
An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors. (2018) (19)
Clinical relevance of interleukin-1 and its multiple biological activities (1987) (19)
Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes. (2018) (19)
An overview on interleukin-1 as a therapeutic agent (1989) (19)
Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? (2014) (19)
InflammationCells and Promote Different Stages of Sterile Recruit Different Myeloid b and IL-1 a IL-1 (2011) (19)
Soluble murine IL-1 receptor type I induces release of constitutive IL-1 alpha. (1999) (18)
Transfer of cytokine-inducing bacterial products across hemodialyzer membranes in the presence of plasma or whole blood. (1996) (18)
Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesis. (1985) (18)
Pyrogenic properties of bleomycin (NSC-125066). (1973) (18)
Recombinant Human Alpha-1 Antitrypsin-Fc Fusion Protein Reduces Mouse Myocardial Inflammatory Injury After Ischemia–Reperfusion Independent of Elastase Inhibition (2016) (18)
A pilot study of cytokine levels and white blood cell counts in the diagnosis of necrotizing fasciitis. (2006) (18)
Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone (2012) (18)
Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. (1994) (18)
Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure. (1991) (18)
Lipid A, the immunostimulatory principle of lipopolysaccharides? (1990) (18)
Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. (1995) (18)
Synthesis of Tumor Necrosis Factor α and lnterleukin-1 Receptor Antagonist, But Not lnterleukin-1, by Human Mononuclear Cells Is Enhanced by Exposure of Whole Blood to Shear Stress (1996) (18)
Bacterial lipopolysaccharide induction of IL-6 in rat telencephalic cells is mediated in part by IL-1. (1993) (18)
Corrigendum: IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity (2016) (18)
Role for interleukin‐1 in the pathogenesis of hypersensitivity diseases (1989) (18)
Administration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. (1994) (17)
Modulation of muramyl dipeptide stimulation of cytokine production by blood components (2009) (17)
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. (1999) (17)
Interleukin-18 treatment options for inflammatory diseases (2005) (17)
Comparison of first use and reuse of cuprophan membranes on interleukin-1 receptor antagonist and interleukin-1 beta production by blood mononuclear cells. (1993) (17)
IL-1 family cytokines as drivers and inhibitors of trained immunity. (2021) (17)
Dissociation of Transcription from Translation of Human IL-1β: Induction of Steady State mRNA by Adherence or Recombinant C5a in the Absence of Translation (1992) (17)
Dissociation of transcription from translation of human IL-1-beta: the induction of steady state mRNA by adherence or recombinant C5a in the absence of translation. (1990) (16)
Detection of interleukin 1 alpha and 1 beta in rabbit tissues during endotoxemia using sensitive radioimmunoassays. (1991) (16)
Interferons as inhibitors of interleukin 1 induced interleukin 1 synthesis. (1989) (16)
Inflammation in human disease: anticytokine therapy. (2009) (16)
Coagulation of whole blood stimulates interleukin-1 beta gene expression. (1995) (16)
Biological consequences of monocyte activation during hemodialysis. (1987) (16)
A short course of oral aspirin increases IL-18-induced interferon-gamma production in whole blood cultures. (2000) (16)
Beyond The Current Paradigm: Recent Advances in The Understanding of Sodium Handling – Guest Editors: Stanley Shaldon and Joerg Vienken: Hyperosmolar Sodium Chloride, p38 Mitogen Activated Protein and Cytokine‐Mediated Inflammation (2009) (16)
Interleukin‐37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome (2019) (16)
Interleukin-18 does not modulate the acute-phase response (2005) (16)
Picogram concentrations of endotoxin stimulate synthesis of IL-1 beta and TNF alpha by human peripheral blood mononuclear cells exposed to recombinant human C5a. (1991) (16)
TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization (2018) (16)
Blocking interleukin-1 and tumor necrosis factor in disease. (1997) (15)
IL‐38 prevents induction of trained immunity by inhibition of mTOR signaling (2021) (15)
Interleukin-1 beta (IL-1 beta), IL-1 receptor antagonist, and TNF alpha production in whole blood. (1992) (15)
Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade (2014) (15)
Rat interleukin-18 binding protein: cloning, expression, and characterization. (2002) (15)
T cell–mediated hepatic inflammation modulates adiponectin levels in mice: role of tumor necrosis factor α (2006) (15)
Differential effects of interleukin-1 alpha and interleukin-1 beta on human peripheral blood eosinophils. (1989) (15)
Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF-alpha, IFN-gamma and glucocorticoids. (2005) (15)
Was the original endogenous pyrogen interleukin-1? (1989) (15)
Fever Produced in the Squirrel Monkey by Human Leukocytic Pyrogen (1979) (15)
The role of protein kinase C in interleukin 1 and tumor necrosis factor alpha induction of fibroblasts to produce and release granulocyte-macrophage colony-stimulating activity. (1990) (15)
Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis (2016) (15)
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease (2008) (15)
Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist. (1993) (15)
Interleukin 37 expression in mice alters sleep responses to inflammatory agents and influenza virus infection (2016) (15)
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses (2018) (15)
Circulating leptin during experimental endotoxemia in humans. (1999) (14)
Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells (1990) (14)
Tumor necrosis factor-alpha causes release of cytosolic interleukin-18 from human neutrophils. (2010) (14)
Human Interleukin-32γ Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice (2018) (14)
Is there a Role for Interleukin‐1 Blockade in Intravenous Immunoglobulin Therapy? (1994) (14)
Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease. (2020) (14)
Functional and morphological effects of interleukin-1β on the perfused rat pancreas (2004) (14)
Molecular mechanisms in endotoxin fever (1983) (14)
Modulation of Liver Inflammation and Fibrosis by Interleukin-37 (2021) (14)
Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways. (2008) (14)
Interleukin 1 receptors and biological responses. (1990) (14)
Single-cell RNA-seq reveals a critical role of novel pro-inflammatory EndMT in mediating adverse remodeling in coronary artery–on–a–chip (2021) (14)
High cytokine levels at admission are associated with fatal outcome in patients with necrotizing fasciitis. (2004) (13)
P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout (2019) (13)
The association of peripheral monocyte derived interleukin 1beta (IL-1beta), IL-1 receptor antagonist, and tumor necrosis factor-alpha with osteoarthritis in the elderly. (1998) (13)
More than inflammation: interleukin-1beta polymorphisms and the lipid metabolism. (2011) (13)
Pharmacokinetics , Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF 2357 ( Givinostat ) (2011) (13)
Hazards of CAPD: Interleukin-1 Production (1986) (13)
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. (2007) (13)
IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8 (2021) (13)
Effects of omega 3 fatty acid supplements on ex vivo synthesis of cytokines in human volunteers. Comparison with oral aspirin and ibuprofen. (1991) (13)
Stem cell factor-deficient mice have a dysregulation of cytokine production during local inflammation. (1998) (13)
Induction of interleukin-1 during CAPD. (1987) (13)
Keep up the heat on IL-1. (2012) (13)
Chemical characterization of an interleukin-1-inducing substance derived from human mixed leukocyte reactions: IL-1-inducing substance is not gamma interferon. (1985) (12)
Interleukin-1 activation and acute phase response during hemodialysis. (1988) (12)
Interleukin-1 and the effects of cyclooxygenase inhibitors on its biological activities. (1989) (12)
Synthesis of interleukin-1β in primary biliary cirrhosis : relationship to treatment with methotrexate or colchicine and disease progression (1995) (12)
Neuroinfl ammation in Alzheimer's disease (2015) (12)
Human Blood Mononuclear Cells (1998) (12)
Granulocyte-macrophage colony-stimulating factor synthesis during experimental endotoxemia in humans. (1992) (12)
Ethanol‐mediated suppression of IL‐37 licenses alcoholic liver disease (2018) (12)
Indeed, IL‐18 is more than an inducer of IFN‐γ (2018) (12)
The Effects of Selective Hematopoietic Expression of Human IL-37 on Systemic Inflammation and Atherosclerosis in LDLr-Deficient Mice (2017) (12)
The effect of fish oil supplementation on plasma α-tocopherol, retionol, lipid and lipoprotein levels in normolipidemic subjects (1991) (12)
Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis. (2003) (12)
Interleukin-1 beta stimulates somatostatin biosynthesis in primary cultures of fetal rat brain. (1989) (12)
The relationship between biocompatibility and interleukin-1. (1987) (12)
Controlling the production of interleukin-1 and tumor necrosis factor in disease. (1995) (12)
IL‐37 regulates allergic inflammation by counterbalancing pro‐inflammatory IL‐1 and IL‐33 (2021) (12)
Effect of protein synthesis inhibitors on leukocytic pyrogen-induced in vitro hypothalamic prostaglandin production. (1985) (12)
Reduced mitogen stimulation of DNA synthesis in human lymphocytes by a human recombinant interleukin-1 receptor antagonist. (1991) (12)
Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma (2020) (11)
Colchicine therapy of familial Mediterranean fever. (1974) (11)
Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist. (1992) (11)
PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis (2019) (11)
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases (2021) (11)
A 36‐year‐old woman with recurrent high‐grade fevers, hypotension, and hypertriglyceridemia (2010) (11)
IL-37 Expression Is Downregulated in Lesional Psoriasis Skin (2020) (11)
Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of ibuprofen. (1989) (11)
Corrigendum: Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation [Rheumatology, 55, (2016), (2220-2229)] doi:10.1093/rheumatology/kew325 (2017) (11)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Leukocyte Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction Treated with Anakinra (2014) (11)
The stimulation of collagenase production in rabbit articular chondrocytes by interleukin-1 is increased by collagens. (1987) (11)
Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon α or γ, human recombinant interleukin-2 and indomethacin (1988) (11)
A Therapeutic use for Interleukin-1 in the Protein-Depleted Animal (1985) (11)
The lysine deacetylase inhibitor givinostat inhibits β-cell IL-1β induced IL-1β transcription and processing (2012) (11)
George Clowes' classic paper and the search for "muscle proteolysis factor". (1996) (11)
187: Interleukin 37 employs the IL-1 family inhibitory receptor SIGIRR and the alpha chain of the IL-18 receptor to suppress innate immunity (2013) (11)
Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling. (2005) (11)
Interleukin-1-induced sleep and febrile responses differentially altered by a muramyl dipeptide derivative. (1989) (10)
Lymphocyte Activating Property of Human Leukocytic Pyrogen (1981) (10)
Effect of oral n-3 fatty acid supplementation on the immune response of young and older women. (1991) (10)
Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial (2015) (10)
Intracellular human IL-1: a precursor for the secreted monokine. (1985) (10)
Interleukin‐37 improves T‐cell‐mediated immunity and chimeric antigen receptor T‐cell therapy in aged backgrounds (2021) (10)
Multiple Interleukin-1 Activities in Luteal Phase Human Plasma (1985) (10)
Intestinal production of interleukin-1 alpha during endotoxemia in the mouse. (1993) (10)
Molecular mechanisms of fever (1998) (10)
IL-1 production by T6 (CD1a) positive cord blood mononuclear cells (Langerhan's cell precursors?). (1989) (10)
Interleukin-1 pretreatment protects against endotoxin-induced hypotension in rabbits: association with decreased tumor necrosis factor levels. (1993) (10)
Interleukin-10 in patients with ST-segment elevation myocardial infarction. (2014) (10)
Comparison of granulocyte-macrophage colony stimulating factor and interleukin-1 production from human peripheral blood mononuclear cells as measured by specific radioimmunoassays. (1992) (10)
The pathophysiology of the pro-inflammatory cytokines (1990) (10)
The combination of soluble IL-18Ralpha and IL-18Rbeta chains inhibits IL-18-induced IFN-gamma. (2002) (10)
Extracellular and nuclear roles of IL-37 after spinal cord injury (2020) (10)
An antibody to a 17 amino acid synthetic peptide of the type I interleukin-1 receptor preferentially blocks interleukin-1 beta binding. (1996) (9)
Cytokine Regulation of Nitric Oxide Production (2002) (9)
A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling (2021) (9)
IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation. (2017) (9)
Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects. (2007) (9)
Interleukin-1β deficiency results in reduced NF-κB levels in pregnant mice (2000) (9)
Lymphokines and bile secretion in the rat. (2008) (9)
Sustained release of IL‐1Ra from biodegradable microspheres prolongs its IL‐1‐neutralizing effects (2005) (9)
Induction of interleukin-1 and tumor necrosis factor during in vitro hemodialysis with different membranes. (1989) (9)
Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 beta converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth. (1999) (9)
The selective ROCK2 inhibitor KD025 reduces IL‐17 secretion in human peripheral blood mononuclear cells independent of IL‐1 and IL‐6 (2018) (9)
The role of interleukin-32 against tuberculosis. (2015) (9)
59 Antiviral and Immunoregulatory Activities of IFN-gamma Depend on Constitutively Expressed IL-1 alpha (2007) (9)
INTERLEUKIN-1 BLOCKADE WITH ANAKINRA TO PREVENT ADVERSE CARDIAC REMODELING FOLLOWING ACUTE MYOCARDIAL INFARCTION: RESULTS OF THE VCU-ART2 PILOT STUDY (2013) (9)
Is there an interleukin-1 genetic predisposition to developing severe sepsis? (1999) (9)
Clinical predictors of response to anakinra in patients with heart failure. (2014) (8)
171 : IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells (2013) (8)
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. (2021) (8)
Targeting of the NLRP3 Inflammasome for early COVID-19 (2021) (8)
Thein vivo andin vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection (1989) (8)
P504Critical role IL-37 to ameliorate endotoxemic cardiac depression in aging mice: a critical role of suppression cardiodepressant cytokines (2014) (8)
Membrane interleukin‐18 revisits membrane IL‐1α in T‐helper type 1 responses (2012) (8)
The NLRP3 inflammasome inhibitor, OLT1177®, ameliorates experimental allergic asthma in mice (2021) (8)
Lymphoblastoid B cell lines produce an interleukin-1-like activity that can be serologically distinct from macrophage interleukin-1. (1986) (8)
Correction: Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistance (2015) (8)
Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia. (1994) (8)
Fever, interleukin-1 and host defense against malignancy. (1982) (8)
The C3a receptor, caspase-1, and release of IL-1β. (2013) (8)
Interleukin-37 Inhibits Colon Carcinogensis During Chronic Colitis (2019) (8)
Role of Complement, Interleukin-1 and Tumor Necrosis Factor in a Local Shwartzman-Like Reaction (1987) (7)
Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury. (1999) (7)
OP0090 The human safe NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of experimental arthritis (2017) (7)
Synergy of helper factors in the differentiation of in vivo-preactivated antigen-specific human B cells. (1985) (7)
Neutralization of IL-18 exerts anti-inflammatory activity in experimental colitis in mice* (2001) (7)
Abstract 8603: Expression of Human Interleukine-37 Protects Mouse Heart Against Ischemic Injury Through Suppression of Monocyte Chemoattractant Protein-1-Mediated Mononuclear Cell Accumulation (2011) (7)
The Role of Interleukin-1 in Septic Shock (1992) (7)
Oxidation of low-density lipoproteins by acellular components of Chlamydia pneumoniae. (2000) (7)
Safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis (2009) (7)
Functional and morphological effects of interleukin-1 beta on the perfused rat pancreas. (1990) (7)
Partial purification of human leukocytic pyrogen (1977) (7)
Interleukin-1 induced T-lymphocyte proliferation and its relation to IL-1 receptors. (1989) (7)
Measurement of Soluble and Membrane‐Bound Interleukin 1 Using a Fibroblast Bioassay (2000) (7)
IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation (2015) (7)
A radioimmunoassay for human interleukin-1 alpha: measurement of IL-1 alpha produced in vitro by human blood mononuclear cells stimulated with endotoxin. (1988) (7)
MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period (2020) (7)
T cell-mediated hepatic inflammation modulates adiponectin levels in mice: role of tumor necrosis factor alpha. (2006) (7)
Implication of the intestinal microbiome as a potential surrogate marker of immune responsiveness to experimental therapies in autoimmune diabetes (2017) (7)
Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention (2012) (7)
IL-1 and related cytokines in innate and adaptive immunity in health and disease (2020) (7)
Characteristics of pyrogen fevers are altered in the aged rabbit (1988) (7)
Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation (2017) (6)
Innate cytokines dictate the fate of acute intestinal inflammation. (2015) (6)
Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases (2019) (6)
30: Anti-IL-37 antibody abrogates the protection in IL-37 transgenic mice to LPS-induced septic shock (2013) (6)
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses (2020) (6)
Ciliary neurotrophic factor combined with soluble receptor inhibits synthesis of proinflammatory cytokines and prostaglandin-E2 in vitro. (1994) (6)
IL:32: A new pro-inflammatory cytokine involved in HCV-related liver inflammation and fibrosis (2009) (6)
[44] Endogenous pyrogens (1988) (6)
Mutation Scan of a Type 1 Diabetes Candidate Gene (2003) (6)
IL-2 receptor gene activation by ATL-derived factor (ADF). (1987) (6)
Interleukin-1: the pros and cons of its clinical relevance. (1988) (6)
Interleukin I and γ interferon induce proliferation of human thymic epithelial cells (1988) (6)
1105: IL-1 Receptor Antagonist Improves Mortality in Severe Sepsis Subset with hemophagocytic Syndrome (2013) (6)
Leukocyte endogenous mediator fails to alter protein dynamics in a model of liver dysfunction. (1989) (5)
Detection of soluble IL-1 receptor type II (IL-1sRII) in sera and plasma from healthy volunteers (1994) (5)
Studies on the biological properties of purified and recombinant human interleukin-1. (1986) (5)
Suppressor αβ T Lymphocytes Control Innate Resistance to Endotoxic Shock (2005) (5)
Treatment of Inflammatory Diseases with IL-1 Blockade (2018) (5)
Low-flux hemodialysis suppresses interferon-gamma production: the possible role of beta2-microglobulin. (2009) (5)
IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response. (2005) (5)
Serum and urinary levels of IL-18 and its inhibitor IL-18 BP in systemic lupus erythematosus (2010) (5)
Soluble tumor necrosis factor receptors inhibit phorbol myristate acetate and cytokine-induced HIV-1 expression chronically infected U1 cells. (1996) (5)
Interleukin-2 production is suppressed by dietary N-3 fatty acids but enhanced by oral aspirin (1989) (5)
Interleukin-1 and dialysis. (1988) (5)
Isolation and Characterization of Human Interleukin-1 mRNA by Molecular Cloning (1985) (5)
Interleukin-38 in Health and Disease. (2022) (5)
CS05-3. Interleukin 37 exerts its anti-inflammatory functions by associating with IL-18Rα and SIGIRR (2011) (5)
163 : Recombinant IL-37 inhibits LPS induced inflammation in a SIGIRR- and MAPK-dependent manner (2013) (5)
IL-38 Gene Deletion Worsens Murine Colitis (2022) (5)
Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury (2021) (5)
Protodyne: an immunomodulatory protein component, prepared from bacillus subtilis (1991) (5)
IL-37 Expression Reduces Lean Body Mass in Mice by Reducing Food Intake (2018) (5)
Protodyne: an immunostimulatory protein component, prepared from gram-positive Bacillus subtilis. (1992) (5)
12: IL-37 protects against obesity-induced inflammation and insulin resistance (2013) (5)
[Antagonists in neonatal sepsis]. (1993) (5)
IL-37 exerts therapeutic effects in experimental autoimmune 1 encephalomyelitis through the receptor complex IL-1 R 5 / IL-1 R 8 2 (2020) (5)
64 – ENDOGENOUS PYROGEN (1981) (4)
Interleukin-1: an important mediator of inflammation (1984) (4)
Interleukin 1 and the brain (1984) (4)
Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagy. (2021) (4)
OP0170 Human il-38 reduces joint inflammation in a mouse model of gouty arthritis (2018) (4)
Attenuation of Inflammatory Disease by Reduction of Interleukin-1 Production or Receptor Antagonism (1991) (4)
Differences in signaling pathways by IL-1 (cid:1) and IL-18 (2004) (4)
Absence of Pyrogenicity by Urinary IL-1 Activity (1985) (4)
The Treatment of Fever from a Clinical Viewpoint (1982) (4)
Circulating interleukin-37 declines with aging in healthy humans: relations to healthspan indicators and IL37 gene SNPs (2022) (4)
A comparison of neutralizing and antigen-binding assays for human antibodies against toxic-shock-syndrome toxin 1. (1984) (4)
The Jeremiah Metzger Lecture. The pathogenesis of fever in human subjects. (1980) (4)
Interleukin-1 stimulation in the ESRD patient: potential long-term consequences. (1987) (4)
Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock. (2005) (4)
Interleukin-1 activity in human plasma (1984) (4)
Decreased whole blood cytokine production during a phase I trial of the histone deacetylase inhibitor ITF2357 (2009) (4)
Effects of Leukocytic Pyrogen (Interleukin-1) on Local Cerebral Glucose Utilization in Rats with and without Premedication with Indomethacin or Dexamethasone (1988) (4)
[Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae]. (1995) (4)
IL‐1 Superfamily and Inflammasome (2017) (4)
Schistosomal egg granuloma-derived fibroblast-stimulating factor is apparently distinct from interleukin-1 (1989) (4)
Studies on the active site of human leukocytic pyrogen (1982) (4)
Measurement of in vivo and in vitroInterleukin-1α levels in mouse stimulated with endotoxin using a radioimmunoassay for murine IL-1α (1991) (4)
The M20 IL-1 inhibitor is distinct from the IL-1ra (1991) (4)
Improvements in host immunity by partially purified interleukin 1 in rats with portacaval anastomosis and splenectomy. (1986) (4)
Dissociation of immunoregulatory function of blood monocytes from maturational state and expression of interleukin-1 in humans chronically infected with Schistosoma mansoni. (1990) (4)
NIH conference. Immunomodulators in clinical medicine. (1987) (4)
Clone controversy at Immunex (1986) (4)
A new micromethod for determination of interleukin-1 production from frozen human blood mononuclear cells. (1987) (4)
IL-18 blockade is a potential disease-modifying therapy for rheumatoid arthritis (2001) (4)
Comment on “Power of Rare Diseases: Found in Translation” (2014) (3)
Correction for Cauchois et al., Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 (2020) (3)
Phorbol myristate acetate-protein complex mimics bioactivity of human IL-1. 1. Direct evidence that PMA temporarily enters and is released from cellular compartment during superinduction protocol. (1985) (3)
Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers (2022) (3)
Pituitary extracts contain a factor which induces thymic epithelial cell proliferation and secretion (1988) (3)
Interleukin-1: multiple biological properties and mechanisms of action. (1987) (3)
The Biology of Interleukin 1, Comparison to Tumor Necrosis Factor and the Effect of the Combination of these Cytokines (1988) (3)
Suppression of endotoxin-inducible cytokines in whole blood from human subjects following single dose of recombinant human interleukin-11 (1999) (3)
Synthesis of interleukin‐1β in primary biliary cirrhosis: Relationship to treatment with methotrexate or colchicine and disease progression (1995) (3)
Incorporation of 3H-thymidine (3H-T) by peripheral blood mononuclear cells (PBMC) from normal subjects and acute myelogenous leukemia (AML) patients is independent of interleukin (IL)-1β converting enzyme (ICE) blockade (1994) (3)
Induction of interleukin-I and interleukin-I receptor antagonist (1997) (3)
P159/O30 OLT1177™, an oral NLRP3 inflammasome inhibitor, inhibits acute joint inflammation and circulating IL 1β during gout flares in humans (2019) (3)
Role of interleukin-1 and tumour necrosis factor-alpha in acute inflammation. (1987) (3)
IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer’s disease mouse model (2021) (3)
Multiple Biological Activities of Human Interleukin-1 (1987) (3)
Grand Challenge in Inflammation (2012) (3)
The Interleukin-1 Family (2014) (3)
Theories of Fever From Antiquity to the Enlightenment (1982) (3)
IL-1-1 History of IL-1 discoveries (2010) (3)
35: Histone deacetylase inhibitors induce indoleamine 2, 3-dioxygenase and modulate dendritic cell functions (2007) (3)
Interleukin 37 employs the IL-1 family orphan receptor SIGIRR and the alpha chain of the IL-18 receptor to inhibit innate immunity (P6293) (2013) (3)
Differential Effects of Anti-IL-1R Accessory Protein Antibodies on IL-1α or IL-1β-induced Production of PGE₂ and IL-6 from 3T3-L1 Cells (2007) (3)
Interleukin-1β and tumor necrosis factor synthesis are differently regulated by cyclic nucleotides in human mononuclear cells☆ (1990) (3)
-containing secretory lysosomes: role of microtubules β Histone deacetylase inhibitors prevent exocytosis of interleukin-1 (2013) (3)
The multiple biological properties of interleukin-1 influencing immunocompetent cells. (1987) (3)
by peripheral blood mononuclear cells is differentially regulated Production of interleukin-1 receptor antagonist and interleukin-1 beta (2011) (3)
Administration of anti‐inflammatory interleukin‐37 ameliorates age‐related vascular, metabolic and physical dysfunction in mice (2017) (3)
Interleukin-1 and Inhibition of Interleukin-1 in Hemodialysis Patients1 (1990) (2)
Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans (2020) (2)
268 A role for intra-cellular interleukin-1alpha in antiviral defense (2008) (2)
Allo-Antigen Expression on Both APCS and Tumor Is Required To Elicit an Effective GVL Response after Experimental Allogeneic BMT. (2004) (2)
To Sheldon M. Wolff, as we commemorate the 10th anniversary of the clonings of IL-1 alpha and IL-1 beta. (1994) (2)
Differential effects of anti-IL-1R accessory protein antibodies on IL-1alpha or IL-1beta-induced production of PGE(2) and IL-6 from 3T3-L1 cells. (2007) (2)
Editorial: Cytokines and Intestinal Mucosal Immunity (2021) (2)
Actions of endotoxin, interleukin-I and tumor-necrosis-factor on arachidonic-acid metabolism in human amnion cells (1987) (2)
Interleukin-18 levels suggest different inflammatory pathways in unstable angina (2003) (2)
Interleukin-lfl (IL-lfl), IL-i receptor antagonist, and TNFa production in whole blood (1992) (2)
Effects of Muscle Strength Training and Tumor Necrosis Factor a (1996) (2)
120 The IL-1 family member IL-1F7 reduces innate immunity by inhibiting Toll-like receptor and IL-1 signaling pathways (2008) (2)
Donor Treatment with α1 Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects (2012) (2)
A Phase I Study of Interleukin-10 in Healthy Humans: Safety and Effects on Cytokine Production (1995) (2)
P105 Identification of rare coding variants in IL-1-related pathways in patients with adult-onset still’s disease (2018) (2)
Author Correction: A guiding map for inflammation (2020) (2)
The IL-1 family: The role of IL-1 and IL-18 in inflammation (2004) (2)
A prior exposure of resting T cells to interleukin 1 decreases their responsiveness to ConA (1988) (2)
Interleukin 1 Production from Various Cells and Measurement of its Multiple Biologic Activities (1988) (2)
Abstract P8 October 4: Lymphokines/cytokines in diseaseShiga toxin inhibition of endothelial cell IL-8, IL-6 and sICAM release is dependent on pre-stimulation with LPS, TNFα or IL-1β (1994) (2)
Interleukin-1 and inhibition of interleukin-1 in hemodialysis patients. (1990) (2)
Caspase-3-independent apoptotic pathways contribute to interleukin-32γ-mediated control of Mycobacterium tuberculosis infection in THP-1 cells (2015) (2)
Role of IL-18 in inflammatory diseases (2009) (2)
Blocking IL-1 and TNF (1999) (2)
The effects of recombinant interleukin-1 receptor antagonist (rlL-1ra) on the adoptive transfer of experimental autoimmune encephalomyelitis (EAE) in rats (1995) (2)
Endo toxin and Tumor Necrosis Factor Induce Interleukin-1 Gene Expression in Adult Human Vascular Endothelial Cells (2007) (2)
Interleukin-1 and biocompatibility in haemodialysis. (1988) (2)
The Biology of Interleukin-1 (Part 2 of 2) (1992) (2)
Interleukin 38 alleviates aortic valve calcification by inhibition of NLRP3 (2022) (2)
Erratum: IL-1 family nomenclature (2011) (2)
INTERLEUKIN-18 (IL-18) And IL-18 binding protein (IL-18bp) And acute graft versus host disease (Gvhd) (2000) (2)
Subject Index, Vol. 1, 1983 (1983) (2)
Interleukin I and II are synergistic on the proliferation of immature T cells (1988) (2)
Suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect by inhibiting histone deacetylation (2004) (2)
Interleukin-1beta deficiency results in reduced NF-kappaB levels in pregnant mice. (2000) (2)
α1 Anti-Trypsin (AAT-1), Augments DCs and Frequency of Regulatory T Cells (T reg), Modulates GVHD, and Increases Survival After Allogeneic Transplantation (2012) (2)
The biology of human interleukin-32 (2007) (1)
The Use of Cytokine Knockouts to Study Host Defense Against Infection (2003) (1)
Traditional and Novel Approaches to Interleukin-1 Antagonism (1995) (1)
Anti-Interleukin-1 Strategies in the Treatment of the Septic Shock Syndrome (1994) (1)
Synergistic activation of natural killer activity by human recombinant interferon alpha or gamma and indomethacin (1986) (1)
Nucleotide sequence of human monocyte interleukin 1 precursor eDNA (2018) (1)
FRI0001 Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation (2016) (1)
647 NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing caspase-3 activity in human melanoma (2016) (1)
Interleukin 1 and interleukin 18 as mediators of inflammation and the (2006) (1)
The Cytokines Interleukin-1 (2005) (1)
The in vivo and in vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection (2017) (1)
Transgene expression of interleukin-37 in IL-10KO mice inhibits colon carcinogensis (2016) (1)
IL-32γ and streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2 (2010) (1)
Interleukin-1 Mediated Autoinflammation from Heart Disease to Cancer (2019) (1)
Myocardial Infarction : The Framingham Heart Study Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without (2003) (1)
Targeting Deacetylases as a Novel Strategy for Prevention of Acute GVHD (2013) (1)
Peptide growth factors and their receptors. Handbook of pharmacology. Volume 95. parts 1 and 2 Edited by M. B. Sporn and A. B. Roberts. Heidelberg: Springer-Verlag. (1990). 794 pp (Part 1) and 727 pp (Part 2). DM 498 (1991) (1)
Interleukin-37 improves aging-associated declines in adaptive immunity leading to enhanced suppression of Ph+ leukemia (2019) (1)
The physiological and pathological effects of cytokines : from the proceedings of the Second International Workshop on Cytokines, held at Hilton Head Island, South Carolina, December 10-14, 1989 (1990) (1)
THE BIOLOGICAL EFFECTS OF PURIFIED AND RECOMBINANT HUMAN INTERLEUKIN-1 (1986) (1)
Characterization ofLimulus Amoebocyte Lysate-Reactive Material fromHollow-Fiber Dialyzers (1984) (1)
Correlation of plasma interleukin-1 (IL-1) and creatine kinase (CK) activities following exercise (1985) (1)
International Workshop on Hemofiltration (1983) (1)
439 The role of IL-37 in psoriasis (2018) (1)
Interleukin-1: Prospects for Biology (1985) (1)
Opposing Effects of Interleukin-36γ and Interleukin-38 on Trained Immunity (2023) (1)
Blocking Cytokines in Infectious Diseases (1992) (1)
IL-32 Expression in Chronic Rhinosinusitis (2010) (1)
Infection Candida albicans against Disseminated Role of Interleukin-18 in Host Defense (2002) (1)
Introduction: Cytokine Biology Relevant to Infectious Diseases (2003) (1)
Mechanism of toxicity of recombinant interleukin 2 (1988) (1)
OP0092 Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration and improves exercise tolerance (2017) (1)
Effect of first use and reuse of cuprophane membrane on interleukin 1 beta il 1 beta production by peripheral blood mononuclear cells pbmc (1991) (1)
Abstract 18066: Novel NLRP3 Inflammasome Inhibitor OLT1177 Reduces Infarct Size in a Mouse Model of Myocardial Ischemia Reperfusion Injury (2017) (1)
Mice Expressing Human Interleukin-32 (IL-32) In The Lungs Are More Resistant To Mycobacterium Tuberculosis (2012) (1)
Mediation by Interleukin-1 of Neutrophil Leukocyte Emigration Induced by Endotoxin1 (1987) (1)
Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon alpha or gamma, human recombinant interleukin-2 and indomethacin. (1988) (1)
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses (2021) (1)
Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. (1989) (1)
Interleukin 1 receptor antagonism abrogates acute pressure-overload induced murine heart failure. (2021) (1)
Abstract 17750: Interleukin-1 Receptor type-1 on Vascular Wall Cells is the Target for the Pro-Atherogenic Effects of Bone Marrow-Derived Interleukin-1{alpha} and Interleukin-1{beta} in Apolipoprotein E-Deficient Mice (2010) (1)
Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory Acute Graft Versus Host Disease (2016) (1)
Circulating interleukin-38 concentrations in healthy adults (2022) (1)
Proinflammatory Cytokines the Nucleus and Down-Regulates The IL-1 Family Member 7 b Translocates to and (2008) (1)
PL-4 IL-36 (Formerly IL-1F7) suppresses innate immunity by inhibiting inflammatory cytokines and dendritic cell activation by association with SMAD3 (2010) (1)
118 A dual role of IL-37 in adaptive immunity (2018) (1)
A critical role for IL-37 in regulatory T cell maintenance and CD4+ T cell inhibition (2019) (1)
Interleukin-10 enhances HIV-1 expression in a chronically infected promonocytic cell line (U1) by a TNFα-independent mechanism (1994) (0)
Manipulation of Cytokine Synthesis Through Dietary Lipids (1993) (0)
Reduced CXCL1 production by endogenous IL-37 expressing dendritic cells does not affect T cell activation (2021) (0)
The effects of IL-1Ra and antisense oligonucleotide to IL-1β converting enzyme (ICE) on the production of IL-1β by acute myeloid leukaemia cells (1997) (0)
Interleukin 32 Expression is Associated with a Unique Subset of Human Dendritic Cells Receptive to the Venezuelan Equine Encephalitis Virus-derived Replicon Vector (2007) (0)
IL-18 in autoimmunity. Studies in autoimmune murine lupus and in human SLE (2007) (0)
Contents, Vol. 1, 1983 (1983) (0)
α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI) (2012) (0)
Mononuclear and NK Cells Production in Human Peripheral Blood g IFN-Papillomavirus 16 Inhibit IL-18-Induced Both E6 and E7 Oncoproteins of Human (2001) (0)
The Role of Monokines in the activation of T cells as assessed by heteroantisera and monoclonal antibodies to human leukocytic pyrogen/lymphocyte activating factor/interleukin 1☆☆☆ (1982) (0)
809 Alpha-1 antitrypsin suppresses melanoma progression through immunological effects in the tumor microenvironment (2017) (0)
IL-1α Neutralization Markedly Ameliorates Crohn's Disease (CD)-Like Ileitis by a Mechanism Altering Gut Microbiome Composition (2017) (0)
hemophagocytic syndrome Severe imbalance of IL-18/IL-18BP in patients with secondary (2013) (0)
Interleukin-1 as a mediator of fatigue in disease: a narrative review (2017) (0)
THP-1 Human Macrophages in Differentiated Mycobacterium tuberculosis IL-32 Is a Host Protective Cytokine against (2010) (0)
Pro-IL-1β Processing is an Essential Step in the Autocrine Regulation of Acute Myeloid Leukaemic Cell Growth (1997) (0)
CYTOKINE, HEMATOLOGIC, AND IMMUNOLOGIC EFFECTS OF INTERLEUKIN‐10 IN HEALTHY HUMANS: 304 (1997) (0)
Interferon-alpha therapy and the IL-18 pathway in chronic hepatitis C patients: IFN-alpha therapy enhances circulating IL-18 binding protein levels (2001) (0)
Ciliary neurotrophic factor is an endogenous pyrogen (fever/cytldnes/thermoregulatlon) (2005) (0)
PL-21 Blocking IL-1 in auto-inflammatory diseases (2008) (0)
Overproduction of Th1 Cytokines Acute Toxoplasmosis Leads to Lethal (2001) (0)
Cellular requirements for interleukin 1 induction with lipopolysaccharides (1988) (0)
Interleukin-1 ( 3 ( IL-1 / 3 ) , IL-1 receptor antagonist , and TNFa production in whole blood (2017) (0)
TRANSPLANTATION a-1-Antitrypsin ( AAT ) – modi fi ed donor cells suppress GVHD but enhance the GVL effect : a role for mitochondrial bioenergetics (2014) (0)
The oral histone deacetylase inhibitor ITF2357 reduces cytokine production, cytokine activities and protects islet β-cells in vivo and in vitro (2009) (0)
FACTOR DURING MIXED LEUKOCYTE REACTIONS (1981) (0)
INTERLEUKIN-1β NEUTRALIZATION AMELIORATES POST-INFARCTION CARDIAC REMODELING IN THE MOUSE (2010) (0)
Osmotic regulation of cytokine synthesis in vitro (osmolarity/stress) (2005) (0)
1434 FEVER , TUMOR NECROSIS FACTOR (1986) (0)
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease (2019) (0)
Il-1 preferentially stimulates the production of a tissue plasminogen-activator by human articular chondrocytes (1986) (0)
Importance Of The Interleukin-1 – Converting Enzyme In Disease Mediated By The Proin.ammatory Cytokines Il-1 And Il-18 (2000) (0)
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes (2013) (0)
TP508, a thrombin‐derived peptide, modulates TLR‐4 dependent cytokine expression in differentiated THP‐1 cells (2009) (0)
A Critical Role for STAT-3 Dependent Induction of Indoleamine 2, 3 Dioxygenase in Histone Deacetylase Inhibitors Mediated the Regulation of GVHD. (2007) (0)
Interleukin-1β-Deficient Mice (1998) (0)
PS2-08 Activated protein C protects the developing lung from hyperoxia-induced lung injury (2010) (0)
via an interleukin-1-mediated event Activated platelets induce endothelial secretion of interleukin-8 in vitro (2011) (0)
111 Knockout of the IL-18 Receptor Chain Enhances the Secretion of Pro-inflammatory Cytokines (2007) (0)
110 Endogenous IL-32 Suppresses HIV-1 (2007) (0)
The effect of alpha-1-antitrypsin on dendritic cell maturation and migration: Possible mechanism for allograft tolerance (2009) (0)
Islet allograft survival and anti-inflammatory cytokine profile are provided by circulating transgenic lung-specific alpha-1-antitrypsin (2009) (0)
Glutaminolysis and Fumar ate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity Graphical (2016) (0)
The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression in CD4+ T-cells and monocytes and induces latent HIV-1 expression in vitro (2009) (0)
The Biological Activities of Human Interleukin-1: Purified and Recombinant Materials (1986) (0)
Issue Information‐ToC (2020) (0)
611 Alpha-1 antitrypsin suppresses melanoma growth by upregulating melanocyte differentiation antigens and enhancing T cell cytotoxicity (2016) (0)
Pathophysiology of Cytokines (1986) (0)
Rapid Publication (2003) (0)
Interleukin-1 and the Treatment of Auto-inflammatory Diseases (2012) (0)
Interleukin-1β and Interleukin-18: Two Cytokine Precursors for Interleukin-1 β Converting Enzyme (Caspase-1) (2002) (0)
Abstract 18369: Interleukin-1 Blockade Improves Exercise Capacity in Heart Failure With Preserved Ejection Fraction (HFpEF): Results of the D-HART Study (2013) (0)
Release of Constitutive IL-1 Soluble Murine IL-1 Receptor Type I Induces (1999) (0)
Endogenous pyrogens. (1988) (0)
311 The effects of cyclosporine on different interleukin-1 activities (1985) (0)
RoleofIL-18inSecond-HandSmoke-InducedEmphysema (2013) (0)
527 Uncovering molecular mechanisms involved in the IL-37-mediated tolerogenic dendritic cells (2019) (0)
Oralaspirin andibuprofen increase cytokine-induced synthesis ofIL-1Jandof tumournecrosis factor-a ex vivo (1996) (0)
Use of inhibitors of IL-18 for the treatment and / or prevention of heart diseases. (2002) (0)
Abstract 16959: Interleukin-1 Blockade in Acute Decompensated Systolic Heart Failure: Results of the Anakinra in Decompensated Heart Failure Pilot Study (2015) (0)
Interleukin-18 binding proteins, the preparation and use of these (1998) (0)
Tu1767 - Blockade of IL-1α Ameliorates Ileitis and DSS Induced Colitis in Samp1/Yitfc Mice by a Mechanism Involving Direct Modulation of the Gut Microbiome (2018) (0)
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment (2018) (0)
Toxic Shock Syndrome Toxin 1 Resistance in Mice is Related to Interleukin 1 Production by Toxic Shock Syndrome Toxin 1 (1989) (0)
Binding Protein Collagen-Induced Arthritis by Murine IL-18 Mechanisms of Inhibition of (2013) (0)
Suberoylanilide hydroxamic acid modulates the innate and allostimulatory responses of dendritic cells and regulates experimental acute graft-versus-host disease (2005) (0)
Human and Bacterial Toll-Interleukin Receptor Domains Exhibit Distinct Dynamic Features and Functions (2022) (0)
3183 – COORDINATE ACTIVATION OF IL-1Β-INDUCED GLYCOLYSIS AND HIF1⍺ STABILIZATION DRIVES TET2-DEFICIENT CLONAL EXPANSION (2022) (0)
PS21 - 102. IL-37 protects against obesity-induced inflammation and insulin resistance in mice (2012) (0)
Review of Tissue-Protective Cytokines (2013) (0)
PS4 - 4. Proteinase 3: a new link between inflammation, obesity and Type 2 Diabetes (2013) (0)
Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation (2016) (0)
Comment on Asgari et al , page 3473 The C 3 a receptor , caspase-1 , and release of IL-1 b (2013) (0)
Abstract 19116: Efficacy of a Small Molecule HDAC Inhibitor in a Model of Diastolic Dysfunction with Preserved Ejection Fraction (2012) (0)
[Demonstration of a bacterial structure in two human mediators: a sleep facilitating factor and a monokine]. (1983) (0)
Proinflammatory Cytokine Responses Neutrophil-Mediated Inhibition of (0)
Production of fever and its effects on the host (1982) (0)
AB0031 Il37 inhibits gag release from human oa cartilage explants (2017) (0)
Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA (2011) (0)
The interleukin-1 family cytokines and receptors in autoimmune and autoinflammatory diseases (2009) (0)
OP0285 Identification of rare coding variants in il-1-related pathways in patients with adult-onset still’s disease (2018) (0)
A7.04 IL-37: Therapeutic potential of a natural inhibitor of innate immunity during acute and chronic experimental arthritis (2016) (0)
Growth promoting effect of recombinant interleukin I and tumor necrosis factor for human astrocytoma cells (1986) (0)
Abstract 8393: IL-18 Binding Protein (IL-18BP) Inhibits {beta}-AR Induced Cardiomyocyte Hypertrophy in vitro and Myocardial Hypertrophy in vivo (2011) (0)
Exploratory analysis of interleukin‐38 in hospitalized COVID‐19 patients (2022) (0)
AREGU January 47/1 (1999) (0)
THU0010 THE ANTI-INFLAMMATORY CYTOKINE INTERLEUKIN 37 IS AN ENDOGENOUS INHIBITOR OF TRAINED IMMUNITY (2019) (0)
Title : 2 IL-37 expression reduces acute and chronic neuroinflammation and 3 rescues cognitive impairment in an Alzheimer ’ s disease mouse model 4 5 (0)
THE EFFECT OF TAUROLIN A WELL CHARACTERIZED PRETREATMENT MODEL OF SEPSIS IN RABBITS (1994) (0)
Cytokine profiles in the erythema migrans skin lesions of Lyme disease (1994) (0)
Interleukin‐1 a (1988) (0)
-Secreting Cells β Bearing Tumors of IL-1 Mediate Suppression of T Cells in Mice CD11b+/Gr-1+ Immature Myeloid Cells (2013) (0)
RoleofInterleukin-1 inAugmenting SerumNeutralization of Bacterial Lipopolysaccharide (1987) (0)
Can a Mendelian Randomization Study Predict the Results of a Clinical Trial? Yes and No (2016) (0)
Measurement of interleukin-1α levels in rats following burn injury using a radioimmunoassay for rat IL-1α (1991) (0)
International Workshop on Monokines and Other Non-Lymphocytic Cytokines Held in Hilton Head, South Carolina on 6-10 December 1987. (1987) (0)
Phase 1/2 trial of vorinostat plus tacrolimus and mycophenolate to prevent graft versus host disease following related donor reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (2014) (0)
Abstract 14648: Interleukin-18 Blockade Prevents Diastolic Dysfunction in a Mouse Model of Heart Failure With Preserved Ejection Fraction (2015) (0)
Il-37 Reduces Neuroinflammation and Rescues Cognitive Impairment in an Alzheimer's Disease Model (2021) (0)
181 The role of nuclear IL-37 in regulating FOXP3 expression and Treg cell stability (2023) (0)
Blunting age-associated chronic inflammation preserves hematopoiesis and immunity and reduces leukemogenesis (2017) (0)
Abstract 994: Tumor NLRP3 drives melanoma progression and immunosuppression by IL-1b-mediated host pro-tumor effects (2020) (0)
Interleukin-32 Expression in the Lungs of Patients with Mycobacterium avium Complex (MAC) Infections. (2009) (0)
Structural requirements for interleukin 1 induction with lipopolysaccharides (1988) (0)
The Role of Interleukin-1 in Mediating Host Defense Mechanisms (1987) (0)
Abstract 12908: Alpha-1 Anti-trypsin Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (2014) (0)
IL-38 regulates intestinal stem cell homeostasis by inducing WNT signaling and beneficial IL-1β secretion (2023) (0)
282 Alpha-1-antitrypsin is an endogenous and specific inhibitor of pro-inflammatory cytokine production in whole blood (2008) (0)
OP0010 Neutralisation of il-18 activity is a disease-modifying therapy in the murine collagen-induced arthritis model (2001) (0)
HUMAN LEUKOCYTCPYROGEN TEST FOR THE DETECTION OF EXOGENOUS FEVER-PRODUCING SUBSTANCES (2017) (0)
Interleukin-32, α1 Anti-Trypsin (AAT-1) and Graft-Versus-Host-Disease (2010) (0)
Colony-stimulating Activity Release by Vascular Endothelial Cells (0)
Interleukin-1, Tumour Necrosis Factor and Treatment of the Septic Shock Syndrome (1992) (0)
Modulators of IL32. (2006) (0)
Immediate Cytokine Responses to Endotoxin: Tumor Necrosis Factor-α and the lnterleukin-1 Family (2020) (0)
Dependent on IL-23 and IL-1 Schistosome Egg Antigen Is Sequentially The Pathogenic Th 17 Cell Response to Major Stadecker (2011) (0)
THE ROLE OF IL‐18 IN SEPSIS: 494 (2004) (0)
Induction and Maintenance of Angiogenesis The Role of Macrophage-Derived IL-1 in White , (2009) (0)
IL-32γ promotes the healing of murine cutaneous lesions caused by Leishmania braziliensis infection in contrast to Leishmania amazonensis (2017) (0)
Human C3a enhances tumor necrosis factor, interleukin-1, and interleukin-6 production in endotoxin-stimulated human PBMC (1994) (0)
Histone Deacetylase Inhibitors Induce Immuno-Dominant Suppression of Dendritic Cells. (2005) (0)
HumanLeukocytic Pyrogen TestforDetection ofPyrogenic Material inGrowthHormoneProduced byRecombinant Escherichia coli (1984) (0)
PAF acts distal to IL-1 in staphylococcal sepsis (1994) (0)
Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions (2023) (0)
HIV-1 Production Endogenous IL-32 Controls Cytokine and (2008) (0)
Haploid genetic dissection of immune molecule trafficking (TECH1P.836) (2014) (0)
IL-1 family member 7 is a fundamental inhibitor of innate immunity (2009) (0)
PLASMA ENDOTOXIN, PLASMA AND STOOL PRO AND AND INFLAMMATORY CYTOKINES AND STOOL SHIGA TOXIN IN PATIENTS WITH SHIGELLOSIS (1998) (0)
Use of inhibitors of interleukin-18 to inhibit tumor metastasis. (2000) (0)
Abstracts of Personal Experience (1996) (0)
Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1). (2017) (0)
Innate Immune Response To Influenza A Infection In Human Alveolar Macrophages (2010) (0)
123 Functions of IL-32 in human vascular endothelial cells (2008) (0)
3-Methylcholantrene Tumor Cells Determining the Immunogenicity of Is Important in a Host-Derived Interleukin-1 (2009) (0)
The Proinflammatory Cytokine Interleukin-32 is expressed in Keratinocytes and Dendritic Cells Obtained from Patients with Chronic Plaque Psoriasis (CPPs) (92.15) (2007) (0)
Cutting Edge Communication Interleukin-18 Binding Protein in Acute Graft versus Host Disease and Engraftment Following Allogeneic Peripheral Blood Stem Cell Transplants (2001) (0)
IL-1-7 Differential roles of IL-1 alpha and IL-1 beta in the malignant process (2010) (0)
INTERLEUKIN‐1&agr; TISSUE LEVELS DURING ENDOTOXEMIA IN THE RAT.: 97 (1997) (0)
Peptides modulating conformational changes: From in silico design to in vivo proof of concept (2011) (0)
Mechanisms of interleukin 1 production and activity role of the 5 lipoxygenase pathway (1987) (0)
Adult-onset Still ’ s disease and myocarditis : successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept (2007) (0)
Use of a cytokine capable of binding IL 18BP and inhibit the activity of a second cytokine (2003) (0)
Humanleukocytic pyrogen: Purification anddevelopment ofaradioimmunoassay (fever/endogenous mediator/immunoadsorption/radiolabeling) (1977) (0)
IL‐18 MEDIATES ENDOTOXIN INDUCED CARDIAC DYSFUNCTION: 216 (2001) (0)
Characterization of the Immune Response in COPD: Study of IL-32 Expression in AAT Deficient and AAT Replete Patients. (2009) (0)
Interleukin-1β and the treatment of auto-inflammatory diseases (ML12) Chairperson: Kouji Matsushima (2010) (0)
Normal in vitro production of TNF in healthy subjects with HLA-DR2 haplotype and in patients with narcolepsy (1989) (0)
Abstract 14752: Recombinant Alpha-1-Antitrypsin Reduces Myocardial Ischemia-Reperfusion Injury in the Mouse (2013) (0)
TheInterleukin-1 Receptor Antagonist Caneither Reduceor EnhancetheLethality ofKlebsiella pneumoniae Sepsis inNewbornRats (1993) (0)
807 LRP1 is a tumor promotor by inhibiting apoptosis in human melanoma (2017) (0)
Characterization of a putative human immunoregulatory protein : the role of Tj 6 an [ H + ] $ ATPase $ like protein in lymphocyte activation (2003) (0)
812 An imbalance between IL-1 and IL-1Ra in human melanoma cells accounts for autoinflammation and contributes to tumor progression in metastatic melanoma (2017) (0)
Human IL-1 cDNA sequences encoding the human biologically active IL-1 proteins (1985) (0)
LIVER CXC CHEMOKINE PRODUCTION AND PMN RECRUITMENT IN VIVO ARE MEDIATED BY CASPASE‐1 DEPENDENT CYTOKINES: 273 (2001) (0)
Up-Regulated During Active Crohn's Disease Endothelial Cells and Macrophages Is IL-18-Binding Protein Expression by (2013) (0)
Abstract 17438: Interleukin-18 Mediates Interleukin-1 Induced Systolic Dysfunction in the Mouse (2012) (0)
Interleukin 32 promotes angiogenesis: a new role for a versatile cytokine. (P6266) (2013) (0)
CARDIOPROTECTIVE EFFECTS OF α1-ANTITRYPSIN IN EXPERIMENTAL ACUTE MYOCARDIAL INFARCTION DUE TO TRANSIENT ISCHEMIA IN THE MOUSE (2010) (0)
Interleukin-1: the paradigm for multifunctional inflammatory cytokines (2009) (0)
Impact of Interleukin-1α on Hyperglycemia-Induced Inflammation and Cell Death in Müller Cells (2013) (0)
Lipopolysaccharide in Humans Inflammatory Responses to Patterns Are Associated with Pulmonary Peripheral Blood Neutrophil Activation (2006) (0)
FEVER, ENDOGENOUS PYROGEN, AND INTERLEUKIN-1 (1999) (0)
PS1-33 Safety and efficacy of ITF2357, an orally active histone deacetylase inhibitor in the treatment of systemic onset juvenile idiopathic arthritis (2010) (0)
Novel insights into the biology of interleukin-32 (2013) (0)
072 The anti-inflammatory cytokine IL-37 inhibits CD4+ T cell activation through the receptor IL-1R8 and supports regulatory T cells (2022) (0)
Interleukin-18 mutants, their preparation and use (2002) (0)
Preparation de molecules bioactives (2000) (0)
INTERLEUKIN-1α TISSUE LEVELS DURING ENDOTOXEMIA IN THE RAT.: 97 (1997) (0)
Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study (2014) (0)
IL-11 ATTENUATES TNF-MEDIATED LUNG INFLAMMATION FOLLOWING ENDOTOXIN (1998) (0)
Inflammation-Restricted Activation Context-Specific and IL-1 Receptor Antagonist Chimeric Protein : (2015) (0)
107 Constitutive Expression of IL-32 Characterizes a Unique Subset of Human Dendritic Cells Receptive to the Venezuelan Equine Encephalitis Virus-Derived Replicon Vector (2007) (0)
Abstract 14434: Oxidized Low Density Lipoprotein Elevates the Pro-osteogenic Activity in Human Aortic Valve Interstitial Cells via Innate Immune Receptors (2016) (0)
EFFECT OF IN VITRO TREATMENT OF ISOLATED HUMAN ISLETS WITH HUMAN ALPHA1-ANTITRYPSIN: 1320 (2008) (0)
Subject Index Vol. 50, 1988 (1988) (0)
IL-32Protection from RNA and DNA Viruses by (2011) (0)
Factor ÃŸIncrease Cell Resistance to Tumor Necrosis Factor Cytotoxicity by Growth Arrest in the G! Phase of the Cell Cycle1 (2006) (0)
Review of Tissue-Protective Cytokines (2013) (0)
101 POSTER Interleukin-18 regulates vascular endothelial growth factor-mediated angiogenesis in hepatic melanoma metastasis (2006) (0)
IL-1 Drives Clonal Hematopoiesis via Selective Induction of Growth Arrest in Normal HSC (2018) (0)
High Affinity Humanized Monoclonal Antibody to Human IL 1β Potently Inhibits Toll-like Receptor (TLR) Agonists in Whole Blood (B61) (2007) (0)
The role of interleukin-18 in inflammation (2007) (0)
PS2-031. IL-32 promotes angiogenesis (2011) (0)
Regulation of Brain Neuropeptide Secretion by Lymphokines. (1987) (0)
Antagonist in neonatal sepsis (1993) (0)
Talabostat augments IL-1β and IL-1α production from peripheral blood monocytes isolated from healthy donors. (2006) (0)
INTERLEUKIN-1 BLOCKADE AMELIORATES LEFT VENTRICULAR REMODELING FOLLOWING ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION - THE VCU-ART PILOT STUDY (2010) (0)
Increase of interleukin-1Ra and interleukin-6 levels during the first two days of hospitalization is associated with raised risk of in-hospital coronary events in unstable angina (1998) (0)
Introduction: surviving septic shock. (1997) (0)
85 Extended Alpha-1-Antitrypsin Monotherapy during Islet Allograft Transplantation in Mice Induces Strain-specific Immune Tolerance (2007) (0)
produced by recombinant Escherichia coli. pyrogenic material in growth hormone Human leukocytic pyrogen test for detection of (2013) (0)
a juxtacrine mechanism Interleukin-1 induces interleukin-8 secretion from endothelial cells by (2011) (0)
Cell-Death Dependent Interleukin-1α Release Activates Host NLRP3 Inflammasome and Promotes Epithelial-Mesenchymal Transition in Metastatic Breast Cancer (2022) (0)
Stem cells engineered to overexpress interleukin 18 binding protein (IL-18-BP) demonstrate maximum growth factor production by MAPK dependent mechanisms (2007) (0)
THE INTERACTION OF MYOCARDIAL DEPRESSANT FACTORS IN ENDOTOXEMIA: ROLE OF TNF-?? IN TLR4- MEDIATED EXPRESSION OF IL-1?? AND ICAM-1 (2006) (0)
The immune system on fire The intracellular logistics of inflammation (2013) (0)
Interleukin-1-Induced Hypotension and the Effect of an Interleukin-1 Receptor Antagonist (1993) (0)
Mice Expressing Human Interleukin-32 (IL-32) In The Lungs Have Increased Lung Compliance And Are More Resistant To Mycobacterium Tuberculosis (2011) (0)

This paper list is powered by the following services:

Other Resources About Charles A. Dinarello

en.wikipedia.org

What Schools Are Affiliated With Charles A. Dinarello?

Charles A. Dinarello is affiliated with the following schools:

Charles A. Dinarello's Academic­Influence.com Rankings